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1. INTRODUCTION 
Modern understanding of osteoarthritis (OA) has largely evolved during 250 
years, previously all forms of chronic arthritis were considered different mani-
festations of gout. In 1782 William Heberden described distinctive osteoarthritic 
changes in fingers and was the first to draw attention to the fact that these were 
not related to gout (Dequeker & Luyten, 2008). Since that time OA has been of 
great interest in clinical practice and in medical research.  
OA is a chronic progressive disease that might affect every diarthrodial joint, 
but clinically the most significant findings can be attributed to knee, hip, spine 
and hand OA. OA has high prevalence, which has doubled since the mid-
twentieth century (Wallace et al. 2017). Solely knee OA affects more than 250 
million people worldwide (Vos et al. 2012). The lifetime risk for developing 
symptomatic knee OA is 45%, which rises to 60% with body mass index (BMI) 
over 30 kg/m2 (Murphy et al. 2008). Although OA has long been considered a 
degenerative cartilage ‘wear and tear’ disease, the paradigm has shifted during 
the recent years. OA damages the whole joint: cartilage, subchondral bone, joint 
capsule, synovial tissue and periarticular muscles. Typical changes in 
progression of OA include cartilage deterioration from superficial fibrillation to 
total denuding of the subchondral bone; osteophytes in the joint margins; cysts 
and attrition of subchondral bone; synovitis; atrophy of the periarticular 
muscles. These changes lead to development of pain (during physical activities 
and night-time at the end-stage), stiffness, swelling, deformity, muscle 
weakness and decreased range of motion. It has been noted in recent years that 
OA is also associated with systemic changes: systemic low-grade inflammation, 
obesity, oxidative stress (OxS), metabolic factors (Berenbaum, 2013; King et al. 
2013; Courties et al. 2015; Lepetsos & Papavassiliou, 2016). The pathogenesis 
of OA is complex and the knowledge of its specific mechanisms is 
inconclusive. Therefore, there is no disease modifying therapy that could 
reverse progression of OA.  
OA is associated with several comorbidities including cardiovascular diseases 
(CVD). It has been found that patients with OA have up to 24% increased CVD 
mortality (Barbour et al. 2015). However, the precise mechanisms behind the 
association between OA and CVD are still largely unknown. Several studies 
have proposed that vascular pathology (i.e. atherosclerosis) might be related to 
pathogenesis of OA (Saleh et al. 2007; Davies-Tuck et al. 2012; Belen et al. 
2016). Atherosclerosis causes systemic arterial damage and leads to premature 
arterial stiffening (Palombo & Kozakova, 2016). Arterial stiffening is the term 
used to describe the structural and functional changes that occur in the arteries 
during ageing and in CVD. The elastic properties of the central arteries (aorta, 
iliac arteries and carotid arteries) are important for cushioning left ventricular 
blood ejection during systole and for the smooth non-pulsatile flow of blood to 
the periphery during diastole (Safar, 2004). In the case of stiffened arteries, the 
high energy pulsatile blood flow reaches the tissue capillaries and causes organ 
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damage. Arterial stiffening is an independent predictor of cardiovascular 
mortality and morbidity (Laurent et al. 2006). Many studies suggest that arterial 
stiffening is associated with systemic inflammation and different biochemical 
alterations (Park & Lakatta, 2012; Kals et al. 2008). However, it remains 
unclear whether arterial pathology induces OA or vice versa because low-grade 
systemic inflammation, a characteristic of OA, might accelerate atherosclerosis 
(Klein-Wieringa et al. 2016; Geng et al. 2016; Hoeven et al. 2013). 
Patients with OA are often multimorbid, which has lead to studies aimed at 
finding potential association between OA and metabolic syndrome (MetS) 
(Sellam & Berenbaum, 2013; Wang et al. 2016a). MetS is a cluster of metabolic 
disorders that include insulin resistance, dyslipidemia, vascular pathology and 
central obesity. Several studies have established that MetS is strongly associated 
with increased state of oxidative stress (OxS) (Keaney et al. 2003; Furukawa et 
al. 2004; Roberts & Sindhu, 2009). 
Obesity has been found to increase the risk of OA (Lementowski & Zelicof, 
2008). Moreover, obesity has been found to be associated with hand OA, which 
suggests a systemic impact of obesity and not only the mechanical overload 
(Visser et al. 2014). Adipokines are white-adipose-tissue derived bioactive 
factors that might play an important role in the pathogenesis of OA (Calvet et al. 
2016). Since adipokines are also associated with CVD risk, they might contribute 
to the association between OA and CVD. Thus, further research is required to 
determine the role of adipokines in the pathogenesis of OA and in CVD.  
Metabolomics is a comprehensive analysis of low molecular weight meta-
bolites, which reflect the state of the human organism at a certain timepoint. 
Metabolites are the intermediates and end-products of different metabolic path-
ways and resemble the end result of the genotype, phenotype and environmental 
factors. Metabolic changes are the most proximal indicators of the disease 
process and drug therapy. Thus, metabolomics is a promising tool in search for 
novel biomarkers that could improve early diagnosis of OA, prognosis of the 
disease and response to therapy.  
The present thesis aims to investigate the role of arterial stiffness in OA and 
to propose new biomarkers that could help to diagnose OA early and predict the 
course of the disease. 
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2. REVIEW OF THE LITERATURE 
2.1 General aspects of osteoarthritis 
Osteoarthritis (OA) is one of the most prevalent chronic diseases of the synovial 
joint, which is associated with a large socioeconomic burden (Hunter et al. 
2014). The most frequently affected joints are the hip, knee, spine and hand. OA 
is the fastest increasing musculoskeletal disorder and the prevalence of knee OA 
has been estimated at 250 million people worldwide (Vos et al. 2012). The 
lifetime risk for developing knee OA is 45%, and it is 61% for obese population 
(Murphy et al. 2008). 
OA damages all components of the diarthrodial joint causing loss of articular 
cartilage, remodelling of subchondral bone, osteophyte formation, ligamentous 
laxity, synovial inflammation and weakening of the periarticular muscles 
(Hutton, 1989). The primary symptoms of OA are pain and decreased range of 
motion and stiffness of the affected joint. Since OA is a heterogeneous disease 
group, there are many approaches to stratify OA into different subtypes. One of 
the most common classifications divides OA into two groups depending on the 
mechanism of onset: primary (idiopathic) and secondary (post-traumatic, 
congenital or developmental diseases, metabolic, inflammatory and other). 
However, several other classifications, based on anatomical components 
(McGonagle et al. 2010) and based on clinical phenotypes (Bijlsma et al. 2011), 
have been proposed. 
 
Assessment of OA severity 
OA can be defined as clinical, radiological or subjective (self-reported). Many 
different techniques have been developed to assess presence of OA and to grade 
the radiological severity of the disease, among them the most widely used 
method is that of Kellgren and Lawrence (Kellgren & Lawrence, 1957). The 
severity of OA falls under 5 categories from 0 to 4 based on joint space width, 
appearance of osteophytes, subchondral sclerosis and cysts: 
Grade 0:  normal joint 
Grade 1:  doubtful narrowing of the joint space and possible osteophytic lipping 
Grade 2:  definite osteophytes and possible narrowing of the joint space 
Grade 3:  moderate multiple osteophyte, definite narrowing of the joint space, 
some sclerosis and possible deformity of bone ends 
Grade 4:  large osteophytes, marked narrowing of the joint space, severe 
sclerosis and definite deformity of bone ends (Kellgren & Lawrence, 
1957). 
 
Several scoring systems have been developed for the clinical evaluation of the 
function and disability of hip OA patients, among them Harris Hip score (HHS), 
Hip disability and Osteoarthritis Outcome Score, Oxford Hip Score, American 
Academy of Orthopaedic Surgeons (AAOS) Hip and Knee Questionnaire 
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(Harris, 1969; Riddle et al. 2008; Nilsdotter & Bremander, 2011). All of these 
scoring systems have been used in clinical studies, but HHS is one of the most 
frequently used physician reported outcome measures for hip joint clinical 
assessment (Hoeksma et al. 2003; Riddle et al. 2008; Shi et al. 2010). HHS 
covers 4 domains: pain, function, absence of deformity and range of motion. It 
has been recently questioned whether range of motion provides any additional 
predictive value (Edwards et al. 2016). Several methods have been devised for 
assessing knee function in OA; the most widely used tests include Hospital for 
Special Surgery (HSS) Knee Score, Western Ontario and McMaster 
Universities Osteoarthritis Index, Oxford Knee Score and others (Marx, 2003). 
HSS Knee Score is a scoring method used for clinical knee joint evaluation 
(Insall et al. 1976), which quantifies pain, function, gait, deformity and range of 
motion (Kovalak et al. 2015; Cholewinski et al. 2015). 
 
Etiopathogenesis of OA 
For long time OA was considered a chronic degenerative disease that was the 
consequence of ageing and “wear and tear” type of damage. Ageing, besides 
obesity, female gender and genetic predisposition, is undoubtedly one of the 
strongest risk factors for OA. However, recent studies have shown that systemic 
inflammation has an important role in development and progression of OA 
(Klein-Wieringa et al. 2016; Sohn et al. 2012; Stannus et al. 2013). The origin 
of inflammation is not clear, but several possible mechanisms have been 
proposed. One proposed scenario is that the components of damaged cartilage 
are released into the synovial fluid and bind to the receptors on synovial cells, 
which activate the production of cartilage-degrading enzymes (e.g. matrix 
metalloproteinases (MMP)) and inflammatory cytokines (Bondeson et al. 2006; 
Sohn et al. 2012). Some authors have supposed that inflammation is driven by 
ageing and introduced the term “inflamm-aging” (Franceschi et al. 2000). 
Inflamm-aging incorporates immunosenescence and age-related metabolic, 
endocrine and nutritional changes that promote the pro-inflammatory state 
(Calçada et al. 2014). According to another view, advanced glycation end-
products, which accumulate in different tissues with age, (including the articular 
cartilage) are involved in the pathogenesis of OA (Sell & Monnier, 1989). Also, 
the role of obesity cannot be underestimated in OA. In addition to mechanical 
wear in the weight-bearing joints, obesity is associated with proinflammatory 
state. Multiple bioactive molecules derived from the adipose tissue have been 
identified, which might have an important role in the pathogenesis of OA 
(Grotle et al. 2008; Poonpet & Honsawek, 2014; Zheng et al. 2016).  
Since OA and CVD share many risk factors, there might be a link between 
the two diseases (Haugen et al. 2015). There are other possible explanations that 
relate vascular pathology with OA. According to Findlay, OA is driven by 
vascular insufficiency (Findlay, 2007). The subchondral bone is highly suscep-
tible to arterial blood flow disruption due to the fact that most of the arterial 
flow comes through epiphyseal artery. Atherosclerosis or embolus in the 
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epiphyseal artery has devastating effects on the subchondral bone and overlying 
cartilage. Another reason for perfusion inadequacy might arise from the venous 
stasis through increased intra-articular pressure, increased loading or thrombus 
formation in the bone vessels (Lucht et al. 1981; Wang et al. 2003). Studies 
have reported hypoxic conditions in the subchondral bone and bone remodelling 
due to hypoxia in OA joints (Pedersen et al. 1989; Chang et al. 2014). In 
addition, other vascular problems have been reported in OA patients (Davies-
Tuck et al. 2012). In conclusion, there is growing body of evidence that vas-
cular changes might play a significant role in development and progression of 
OA. 
 
 
2.2 Osteoarthritis and cardiovascular diseases 
OA is associated with many comorbidities and one of the most important 
disease groups related to OA is CVD (van Dijk et al. 2008; Leite et al. 2011). 
Recent evidence suggests that patients with severe CVD are more likely to 
require joint arthroplasty (Kadam et al. 2011). Finding out more details about 
the co-existence of OA and CVD might help to develop better CVD risk 
management strategies and to provide insights into the pathophysiology of OA. 
 
 
2.2.1 Increased cardiovascular risk in osteoarthritis 
Many studies have shown that OA patients have increased CVD prevalence and 
mortality (Rahman et al. 2013; Hawker et al. 2014; Hall et al. 2016; Wang et al. 
2016b). The Rotterdam study found independent association between athero-
sclerotic changes and presence and progression of hip, knee and hand OA 
(Hoeven et al. 2013). A nation-wide population study with over 90,000 partici-
pants reported that OA carries an increased risk for acute coronary syndrome 
(Chung et al. 2016). The Framingham heart study demonstrated increased 
incidence of coronary heart disease in symptomatic hand OA patients (Haugen 
et al. 2015). Furthermore, the AGES Reykjavik study in which 5300 subjects’ 
coronary calcifications and carotid plaque severity were assessed, found linear 
association between severity of hand OA and atherosclerosis (Jonsson et al. 
2009). Consequently, CVD and OA seem to be related. In order to improve the 
treatment of OA patients, we need to find out more about the mechanisms 
behind the interplay of these two major health concerns. The overlapping of risk 
factors, including obesity, ageing, decreased physical activity, increased use of 
non-steroidal anti-inflammatory drugs, metabolic factors and inflammation, 
cannot be overlooked (Stürmer et al. 1998, 2001; Yusuf et al. 2010; Trelle et al. 
2011). However, there might be direct relationship between OA and vascular 
damage (Ghosh & Cheras, 2001; Conaghan et al. 2005). A study investigating 
knee bone marrow lesions (a surrogate marker for OA) found wider retinal 
venular calibre in subjects with signs of early OA (Davies-Tuck et al. 2012). 
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These results suggest systemic vascular involvement already in the early phase 
of OA. Another study determined aortic elasticity, using echocardiography in 
knee OA patients and found decreased aortic elasticity in OA patients (Belen et 
al. 2016). Furthermore, hand OA has been associated with increased arterial 
stiffness even though it was largely attributable to the confounding effect of age 
(Saleh et al. 2007). However, Goldsmith et al. (Goldsmith et al. 2014) found 
that large artery elasticity characteristics were not associated with the size or 
presence of bone marrow lesions. Altogether, there are only a few studies 
investigating the associations between OA and arterial stiffness and the results 
are inconsistent. Hence, drawing valid conclusions at the present is difficult and 
new studies are highly warranted.  
The current thesis aims to provide a broader cardiovascular profile of OA 
patients with emphasis on arterial stiffness, but also taking into account the 
traditional risk factors (obesity, lipid metabolism, glucose metabolism, hyper-
tension, tobacco use and different inflammatory markers).  
 
 
2.2.2 Arterial function and cardiovascular diseases 
The paramount role of vascular function in the pathogenesis of CVD has been 
undoubtedly established. Arterial stiffness has emerged as one of the earliest 
and independent determinants of cardiovascular morbidity and mortality 
(Laurent et al. 2001; Vlachopoulos et al. 2010). Increase in aortic stiffness is a 
hallmark of the ageing process and the consequence of many diseases like 
atherosclerosis, diabetes and chronic renal insufficiency (Lyle & Raaz, 2017). 
However, the precise mechanisms behind the development of arterial stiffening 
are largely unknown and remain to be discovered.  
Arteries are the conduit vessels that provide the blood flow from the heart to 
the peripheral organs. The parameters of the arteries vary in wall structure and 
function depending on the location. The central arteries are more elastic and the 
peripheral arteries contain a thicker muscle layer and produce more resistance 
(Zieman et al. 2005). The arterial wall consists of 3 layers: intima, media and 
adventitia. These layers work together sensing and responding to acute changes 
in blood pressure (BP) by dilation and constriction (Zieman et al. 2005). The 
intima is the innermost layer and consists of a single layer of endothelial cells 
and functions as antithrombotic surface. The media consists of elastic lamellae, 
collagen and vascular smooth muscle cells and is responsible for the elastic 
properties of the arterial wall and the ability to dilate and contract. The 
outermost layer is the adventitia which is composed of fibroblasts and collagen 
(Lyle & Raaz, 2017). Elastin bears most of the load at lower pressures and 
collagen supports the arterial wall at higher pressures. In the case of increased 
arterial stiffness, the content of elastic elastin fibres is reduced and the content 
of stiffer collagen fibres is increased, which has also been observed in the 
inflammatory milieu (Johnson et al. 2001). In addition, cellular content is 
changed including infiltration of smooth muscle cells and macrophages and 
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increased expression of MMP, transforming growth factor beta and cytokines 
(Lakatta, 2003). Another functional determinant of arterial stiffness is mediated 
by paracrine mediators such as angiotensin (Dzau, 1986), endothelin 
(Yanagisawa et al. 1988) and nitric oxide (NO) (d’Alessio, 2004). Impaired 
production and action of NO lead to endothelial dysfunction that is a feature of 
arterial stiffness (Matz et al. 2000).  
The pathogenesis of arterial stiffness is complex involving several estab-
lished mechanisms. Ageing is one of the strongest risk factors for arterial stiff-
ness (Laurent et al. 2006). The potential pathways through which ageing affects 
arterial stiffening are accumulation of advanced glycation end-products, 
inflammation, elastin fractures and calcification (Wang et al. 2007; Lyle & 
Raaz, 2017). Another condition that is closely related to arterial stiffness is 
hypertension. However, whether arterial stiffness is induced by hypertension 
(increased elastin degradation from pulsatile aortic wall stress (O’Rourke & 
Mancia, 1999)), or whether hypertension is the result of increased arterial 
stiffness is a matter of debate (Dernellis & Panaretou, 2005).  
Metabolic disorders too have been linked to increased arterial stiffness. 
Increased arterial stiffening is one of the major complications of diabetes 
mellitus (Stehouwer et al. 2008). An important mechanism that leads to organ 
damage in MetS is generated by OxS (Roberts & Sindhu, 2009). OxS has been 
found to induce endothelial dysfunction by decreasing NO bioavailability due to 
reactive oxygen species (Lyle & Raaz, 2017). A possible source for the 
excessive amount of reactive oxygen species might be the mitochondria (Zhou 
et al. 2012). Another major reversible risk factor for arterial stiffness is smoking 
(Mahmud & Feely, 2003). However, the effects of cigarette smoking on the 
arterial stiffness of different segments of arteries are still unclear and need 
further research (McEvoy et al. 2015). 
   
 
2.2.2.1 Measures of arterial stiffness 
Arterial stiffness can be quantified using invasive and non-invasive techniques. 
Owing to the rapid development of the non-invasive methodology that enables 
to measure arterial stiffness relatively fast with high validity, in the majority of 
studies use non-invasive methods (Laurent et al. 2006). Pulse wave velocity 
(PWV) resembles the speed of a pressure wave travelling through the arterial 
tree and is directly associated with the elastic modulus of the vessel. In stiffer 
arteries PWV is increased. Carotid to femoral pulse wave velocity (cf-PWV) is 
considered the ‘gold standard method’ for measuring arterial stiffness 
(Townsend et al. 2015). There are various techniques for measuring PWV: 1) 
using a tonometer or a probe to acquire the pulse wave with a transducer; 2) 
using cuffs placed around the neck or limbs to determine the arrival of the pulse 
wave oscillometrically; 3) using ultrasonography; 4) using the magnetic reso-
nance imaging-based approach (Townsend et al. 2015). One of the most 
widespread techniques for determining the cf-PWV is applanation tonometry. 
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The arterial pressure waves generated by the heart travel through the arterial 
system. The pressure wave is a composite of the forward travelling waves and 
wave reflections (Koh et al. 1998). Waves are reflected mainly from the 
branching points of arteries and other impedance mismatch sites (Laurent et al. 
2006). In healthy vessels, reflected waves return to the aortic root in diastole, 
thereby increasing diastolic pressure. However, in stiffened arteries, waves 
arrive earlier in end-systole and augment systolic pressure (Nichols & Edwards, 
2001). This can be quantified by means of augmentation index (Aix) (Town-
send et al. 2015). However, some studies that account of the reservoir function 
of aorta, which markedly reduces the contribution of wave reflections to central 
BP augmentation, thus questioning the magnitude of impact from reflected 
waves (Tyberg et al. 2009; Davies et al. 2010; Davies-Tuck et al. 2012). 
Measurement of central hemodynamics can be made invasively or non-
invasively, the latter being more appropriate in the clinical setting. Non-invasive 
pulse wave analysis (PWA) uses pressure waves from the carotid, brachial or 
radial artery and central pressure waveforms are calculated using transfer 
function or special algorithms (Townsend et al. 2015). Measurement of 
peripheral BP is of great importance for calibration and accurate results. Using 
pressure waves and simultaneously obtained or estimated flow waves, 
separation analysis can be applied to record the amplitudes of forward and 
backward travelling waves (Kips et al. 2009). Another method has been 
developed based on the electric circuit (employing a modified Windkessel 
model), which enables to measure proximal capacitive and peripheral 
oscillatory compliance (Cohn et al. 1995). In the case of this technique, a sensor 
on the radial artery identifies reflections in diastole as a decaying sinusoidal 
wave that is largely affected by the decreased buffering function of the aorta 
(Cohn et al. 1995; McVeigh, 2003).  
 
 
2.2.2.2 Prognostic value of arterial stiffness 
Arterial stiffness has been found to predict multiple end-organ complications. 
Arterial stiffness measured as cf-PWV is an independent predictor of cardio-
vascular and all-cause mortality (Laurent et al. 2001; Vlachopoulos et al. 2010; 
Townsend et al. 2015). However, data about carotid to radial PWV (cr-PWV) 
and its possible predictive properties are inconsistent (Pannier et al. 2005; 
Young-Soo et al. 2006; Townsend et al. 2015). Recently, increased aortic 
stiffness coupled with decreased brachial stiffness independently predicted 
mortality in dialysis population, thus challenging the ‘gold standard’ (Fortier et 
al. 2015; Covic & Siriopol, 2015). Increased arterial stiffness leads to an 
increase in systolic arterial pressure and a decrease in diastolic arterial pressure, 
resulting in isolated systolic hypertension, the most common form of hyper-
tension in the elderly, causing excess morbidity and mortality (Franklin et al. 
1997). Apart from being the cause of causing heart failure (Tsao et al. 2015), 
increased aortic stiffness leads to higher pulsatile pressures in the vulnerable 
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microcirculation of many organs. Therefore, increased arterial stiffness is 
related to cerebral small vessel disease and cognitive impairment (Fukuhara et 
al. 2006; Ding et al. 2015; Pase et al. 2016). Atherosclerosis leads to increased 
arterial stiffening and loss of small artery elasticity, which is an independent 
prognostic factor in patients with peripheral arterial disease (Kals et al. 2014). 
Also, arterial stiffening has been shown to accelerate renal insufficiency in 
chronic kidney disease (Selwaness et al. 2014). In conclusion, increased arterial 
stiffness is associated with not only increased CVD but also with other end-
organ dysfunctions (Lyle & Raaz, 2017). 
 
 
2.3 The role of adipokines in osteoarthritis and 
cardiovascular diseases 
The former view of the adipose tissue as a passive reservoir for storing energy is 
no longer valid. The adipose tissue is now acknowledged as a metabolically 
active tissue that has great importance in regulating homeostasis in normal and 
disease conditions (Raucci et al. 2013). Adipokines are mainly white adipose 
tissue derived proteins that might be associated with OA and CVD (Hu et al. 
2011; Mattu & Randeva, 2013). The most thoroughly studied and clinically 
promising adipokines are leptin, adiponectin and resistin. 
 
 
2.3.1 Leptin 
Leptin is a 16 kDa non-glycosylated protein that is encoded by the LEP gene 
and was the first identified adipokine (Zhang et al. 1994). After leptin, hundreds 
of adipose tissue synthesised bioactive molecules have been discovered (Raucci 
et al. 2013). Leptin acts through its receptor OB-Rb that is encoded by the 
diabetes gene. This adipokine is mainly produced by adipocytes and its 
circulating levels are highly dependent on white adipose tissue mass (Conde et 
al. 2011). One of the most important roles of leptin is regulation of appetite and 
energy expenditure by inducing anorexigenic and supressing orexigenic factors 
(Ahima et al. 1996). In obese subjects the levels of leptin are high, which 
correlates with increased adipose tissue mass; however, normal appetite cont-
rolling mechanisms do not function properly and resistance to leptin develops 
(Ahima et al. 2006). Leptin has been associated with immunomodulation (Lam 
& Lu, 2007) and inflammation (Iikuni et al. 2008). 
During the last decade interest in the association between leptin and OA has 
grown significantly. OA patients have increased levels of leptin in the synovial 
fluid as well as in the serum (de Boer et al. 2012). It has been suggested that 
leptin serves as the link between OA and obesity since the risk for developing 
OA does not increase in obese leptin gene knockout mice (Aspden, 2011). 
Leptin has been found to have an anabolic effect on cartilage in obese OA 
patients, however, there is accumulating evidence suggesting its proinflam-
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matory action (Dumond et al. 2003; Hu et al. 2011). Leptin increases the levels 
of proteolytic enzymes like MMP (Toussirot et al. 2007). In addition, this 
adipokine has increased expression in osteoblasts (Mutabaruka et al. 2010). 
Furthermore, a recent study found that leptin levels were associated with knee 
OA progression and total joint replacement (Martel-Pelletier et al. 2016).  
Besides OA, leptin has been found to be associated with CVD. The possible 
interaction with CVD is attributable its proinflammatory properties and to 
obesity related changes (Martin et al. 2008). Leptin has been linked to coronary 
heart disease and heart failure in prospective studies (Sattar et al. 2009; 
Wannamethee et al. 2011), as well as with arterial stiffness (Tsai et al. 2016), 
insulin resistance (Mantzoros et al. 1998) and OxS (Bouloumie et al. 1999). 
However, several studies question the role of leptin in development of CVD 
(Bidulescu et al. 2013; Martin et al. 2015). Altogether, leptin might play a key 
role in the pathogenesis of OA and may also be involved in development of 
CVD. 
 
 
2.3.2 Adiponectin 
Adiponectin is a 30 kDa protein that is mostly produced in the adipose tissue 
and is present in the serum in three forms: trimer, hexamer and high molecular 
weight (Kadowaki et al. 2006). Adiponectin acts through two major functio-
nally distinct receptors, AdipoR1 and AdipoR2 (Kadowaki & Yamauchi, 2005). 
Adiponectin circulates in serum at high concentrations 5-30 µg/mL. Unlike 
leptin, adiponectin is inversely correlated with BMI and the plasma levels of 
leptin are decreased in obese patients (De Rosa et al. 2013). Adiponectin is 
widely recognised by its anti-inflammatory, anti-atherogenic and anti-diabetic 
properties and is differently expressed in men and women (Kern et al. 2003; 
Ohashi et al. 2012). This adipokine serves many functions in the human 
organism, such as energy metabolism (Lee & Shao, 2014) and inflammatory 
response modulation (Takemura et al. 2007). 
The results of studies assessing adiponectin in relation to OA provide 
contradictory results. Adiponectin has been negatively associated with radio-
graphic OA severity, which suggests the protective role of this adipokine in OA 
(Honsawek & Chayanupatkul, 2010; Zheng et al. 2016). However, higher 
adiponectin levels have been found in radiographically most severe OA (Kos-
kinen et al. 2011) and in patients with erosive hand OA compared with non-
erosive OA (Filková et al. 2009). These conflicting results might be caused by 
different isoforms of adiponectin, which act differently. Adiponectin has been 
found to upregulate MMP and inflammatory markers in primary human 
chondrocytes (Koskinen et al. 2011). Thus, the role of adiponectin, which is 
often thought of as protective adipokine, needs further research. 
Furthermore, adiponectin seems to play role in the pathogenesis of CVD as 
well. Lower adiponectin levels have been found in symptomatic coronary artery 
disease patients (Kumada et al. 2003). Yet, high adiponectin levels at baseline 
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in prospective studies have been associated with increased mortality and CVD 
morbidity (Wu et al. 2014; Witberg et al. 2016). Since adiponectin has many 
anti-inflammatory properties (Ouchi et al. 1999; Kobashi et al. 2005), the 
upregulation might be secondary reaction in order to protect cells from 
excessive inflammatory cascade activation. Plasma adiponectin levels have 
been associated with progression of arterial stiffness in hypertensive patients 
(Youn et al. 2013). Hypoadiponectinemia has been found to be an independent 
correlate of excess arterial stiffness in young black adults (Nguyen et al. 2008). 
The role of adiponectin requires further research involving different disease and 
population groups. 
 
 
2.3.3 Resistin 
Resistin is a 12.5 kDa cysteine-rich protein that was first described in 2001 as a 
mediator of insulin resistance in obese mice (Steppan et al. 2001a). Resistin 
belongs to a family of tissue-specific resistin-like molecules (Steppan et al. 
2001b). It consists of 108 amino acid prepeptides that circulate as dimeric 
proteins. The main source of resistin in the human body is mononuclear cells, 
outside the adipose tissue (Filková et al. 2013). Resistin is involved in the 
secretion of pro-inflammatory mediators and recruitment of other immune cells 
which associates this adipokine with many inflammatory conditions (Bokarewa 
et al. 2005; Silswal et al. 2005).  
Higher levels of resistin have been found in OA patients compared with non-
OA controls (Li et al. 2014). Resistin is expressed in the synovial fluid of OA 
joints (Presle et al. 2006). This adipokine is associated with increased release of 
inflammatory mediators from articular cartilage and with activation of MMP 
leading to cartilage degradation (Lee et al. 2009; Koskinen et al. 2014). Resistin 
has even been proposed as a possible drug target in OA (Koskinen et al. 2014).  
Increasing evidence associates resistin with atherogenesis (Reilly et al. 2005; 
Jung et al. 2006). Resistin has been found to independently predict myocardial 
infarction, cardiovascular death and restenosis in patients undergoing percu-
taneous coronary intervention (On et al. 2007; Momiyama et al. 2011; Kreçki et 
al. 2011; Fontana et al. 2015). In addition, resistin might be associated with 
worse outcome after ischaemic stroke independently of other predictors 
(Efstathiou et al. 2007). Plasma resistin levels have been found to correlate with 
determinants of MetS, a known CVD risk factor (Norata et al. 2007). In 
conclusion, resistin is related to many diseases including OA and CVD and the 
key mechanisms seem to be associated with inflammation. 
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2.4 Metabolic syndrome and  
metabolomic profiling of osteoarthritis 
MetS is a composite of central obesity, hypertension, atherogenic dyslipidemia, 
hyperglycaemia and insulin resistance (Grundy et al. 2004). For diagnosis of 
MetS, at least 3 of the 5 characteristics must be present: increased waist 
circumference, high triglyceride level, low level of high-density lipoprotein 
(HDL) cholesterol, hypertension and increased fasting glucose (Grundy et al. 
2005). MetS increases the risk for coronary heart disease and stroke threefold 
and cardiovascular mortality fivefold (Isomaa et al. 2001). Also high-grade OxS 
has been considered a hallmark of MetS (Ford et al. 2003; Fortuño et al. 2006). 
Even though MetS was first acknowledged as a major risk factor for CVD, 
recent studies have linked MetS with other diseases including OA (Le Clanche 
et al. 2016). 
 
 
2.4.1 Metabolic factors and osteoarthritis 
It has been reported that OA patients have increased prevalence of MetS 
(Puenpatom & Victor, 2009). According to the data of NHANES III, 59% of the 
patients with OA had MetS compared with 23% of the persons in the population 
without OA (Puenpatom & Victor, 2009). Thus the association between OA and 
MetS is worth exploring. 
Hypertension is a prevalent condition in OA patients and it has been 
demonstrated that among 1000 patients with hip OA, 55% had hypertension or 
CVD (Marks & Allegrante, 2002). There are several possible explanations for 
how OA is linked to hypertension. OA patients have decreased physical activity 
that is a known risk factor for hypertension (Huai et al. 2013). OA patients use 
often non-steroidal anti-inflammatory drugs, which might be associated with 
hypertension or might interfere with hypertension treatment (Aljadhey et al. 
2012). However, since vascular pathology presumably plays a role in the 
pathogenesis of OA, then OA might be the result of vascular damage (Findlay, 
2007). Hypertension is also associated with other components of MetS, 
especially visceral obesity (Hayashi et al. 2004). 
Central obesity is a growing health concern that has been associated with 
OA progression and increased disability (Felson et al. 1988; Cooper et al. 2000; 
Nishimura et al. 2011). Obesity results in increased loading of the weight-
bearing joints that lead to activation of mechanoreceptors that induce the 
expression of cytokines and proteolytic enzymes (Pottie et al. 2006). However, 
obesity has also been associated with hand OA that is not affected by weight 
bearing (Visser et al. 2014). This suggests that the association between obesity 
and OA is more complex. Data from Osteoarthritis Initiative suggests that OA 
patients with normal BMI and central obesity have a higher risk of decline in 
physical activity and function, therefore, they might benefit from obesity related 
complication risk reclassification (Batsis et al. 2015). In addition, central 
24 
obesity is associated with the dysbalance of adipokines, which has impact on 
OA progression (Poonpet & Honsawek, 2014), CVD risk (Nakamura et al. 
2014), insulin resistance, dyslipidemia and inflammation (Jung & Choi, 2014).  
Dyslipidemia is an important component of MetS that is interrelated with 
the other components. MetS is associated with excess calories intake due to a 
high fat diet that leads to accumulation of lipids in different tissues (McGavock 
et al. 2006; Harasim et al. 2015). Articular chondrocytes express fatty acid and 
cholesterol transport proteins and receptors for low-density lipoprotein (LDL)-
cholesterol. A characteristic feature of OA in chondrocytes is accumulation of 
cholesterol and fatty acids (Kosinska et al. 2013). One of the reasons for this 
might be impaired efflux of lipids in OA chondrocytes due to the decreased 
gene expression of efflux regulating genes (Tsezou et al. 2010). In addition, 
metabolism of free fatty acids can lead to high grade OxS that is associated with 
cartilage damage as well as with increased arterial stiffness (Yudoh et al. 2005; 
Kals et al. 2008). Serum cholesterol and triglyceride levels have been found to 
be associated with the incidence of bone marrow lesions in a prospective study 
(Davies-Tuck et al. 2012). HDL-cholesterol has anti-inflammatory properties 
and has been found to be protective of bone marrow lesions (Doré et al. 2012), 
however OA patients have lower levels of HDL-cholesterol (Karvonen-
Gutierrez et al. 2012). In general, dyslipidemia might have an important role in 
the pathogenesis of OA, but the knowledge is insufficient and needs further 
research in order to determine, whether lipid metabolism biomarkers could be 
used as diagnostic and prognostic markers for OA. 
Insulin resistance has been considered to be the core component of MetS. 
Glucose can modulate anabolic and catabolic genes including the genes of 
MMP 1 and 13 in articular chondrocytes (Rosa et al. 2011). In diabetic mice, 
chondrocytes became resistant to insulin growth factor I that mediates anabolic 
effects (Di Cola et al. 1997). Hyperglycemia results in development of a chronic 
pro-inflammatory environment and further interferes with the insulin receptor 
pathway, which leads to excessive OxS (Saudek & Kay, 2003; Rosa et al. 
2009). A meta-analysis of the associations between OA and diabetes found that 
OA was more prevalent in diabetes patients (Louati et al. 2015). Hyper-
glycaemia has been found to be associated with increased symptoms of pain, 
disability and depression in OA patients (Li et al. 2016). Hyperglycemia might 
play central role in the pathogenesis of OA by causing low-grade inflammation 
(Stannus et al. 2010), cartilage damage, subchondral bone changes (Zhuo et al. 
2012) and high-grade OxS (Rosa et al. 2009).  
 
 
2.4.2 Oxidative stress and osteoarthritis 
OxS is characterised by imbalance between the production and neutralisation of 
free radicals and active metabolites (Sies & Cadenas, 1985; Majima et al. 
2016). Reactive oxygen species and reactive nitrogen species have an important 
role in normal physiological conditions (Nathan, 2003). However, in excessive 
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quantities they cause damage to proteins, carbohydrates, lipids and DNA, 
leading to possible cell death (Rahman et al. 2012). To cope with excessive 
OxS, the organism has several antioxidant mechanisms that are enzymatic and 
nonenzymatic and usually succeed in blocking the harmful effects of free 
radicals. The enzymatic antioxidant system consists of catalase, superoxide 
dismutase and glutathione peroxidase among others (Rahman et al. 2012). Since 
superoxide is the primary reactive oxygen species, its dismutation by super-
oxide dismutase is of primary importance for each cell (Birben et al. 2012). 
Nonenzymatic antioxidants include low-molecular-weight compounds such as 
vitamin C, vitamin E, glutathione, carotenoids and uric acid (Birben et al. 
2012).  
In pathological conditions the natural defence system fails to neutralise the 
reactive oxygen species and TAC is reduced. High grade OxS has been 
implicated into multiple pathological conditions including OA (Maneesh et al. 
2005; Ziskoven et al. 2010). It has been noted that in OA the amount of total 
peroxides overwhelms antioxidant capacity, thus leading to overt OxS. Patients 
with OA have increased markers of OxS (Altindag et al. 2007). OxS has a 
major role in modulating chondrocyte function (Mazzetti et al. 2001), in 
inducing synovial fibroblast death (Jovanovic et al. 2002) and subchondral bone 
remodelling (Boileau et al. 2009), and in decreasing the resynthesis of collagen 
in OA (Altindag et al. 2007). Therefore, OxS might play a crucial role in 
development and progression of OA. Moreover, OxS has an important role in 
endothelial dysfunction and increased arterial stiffness (Kals et al. 2008; Kim et 
al. 2013). 
Oxidized LDL (oxLDL) is the result of the impact of excessive OxS on 
LDL-cholesterol. OxLDL is a mixture of heterogeneously modified LDL 
particles that consist of different oxidized lipids and amino acid residues (Itabe, 
2012). Precise mechanisms by which LDL is oxidized are largely unknown. 
oxLDL acts through several receptors that include the lectin-like oxLDL 
receptor-1 (Yoshida et al. 1998). The receptors of oxLDL are expressed on 
multiple cells including endothelial cells and macrophages (Kodama et al. 
1988). Activation of these receptors by oxLDL leads to the phenotype shift into 
active inflammatory cytokine producing cells (van Tits et al. 2011). Therefore, 
oxLDL can also be viewed as a biomarker of inflammation (van Tits et al. 
2011; Tekin et al. 2013; de Munter et al. 2013). Furthermore, oxLDL has a role 
in the pathogenesis of OA. After oxLDL has been taken up by chondrocytes, it 
induces OxS, which leads to cartilage damage (Akagi et al. 2009). Animal 
studies have demonstrated that LDL accumulates in the synovial lining and 
leads to activation of the synovium and osteophyte formation while the uptake 
of oxLDL by macrophages has been associated with activation of TGF-β (de 
Munter et al. 2013). In addition to being involved in the pathogenesis of OA, 
ox-LDL has also been associated with arterial stiffening (Brinkley et al. 2009), 
endothelial dysfunction (Cominacini et al. 2000) and CVD (Bliden et al. 2016).  
 
 
26 
2.4.3 Matrix metalloproteinase 3 and osteoarthritis 
MMP3 is also known as stromelysin-1 and the MMP3 encoding gene is situated 
on chromosome 11. MMP3 is a 59/57 kDa zymogen that after secretion is 
proteolytically processed into 28 kDa and 45 kDa active forms (Chen et al. 
2014). MMP3 belongs to the family of MMP that are responsible for degra-
dation of different substrates and regulate cell-matrix composition (Chakraborti 
et al. 2003). The family of MMPs are zinc-dependent endopeptidases that have 
the ability to cleave extracellular matrix constituents and non-matrix proteins 
(Massova et al. 1998). MMPs regulate the remodelling and turnover of the 
extracellular matrix, which in addition to structural support, play an important 
role in signalling and participate in cell proliferation, differentiation and death 
(Chakraborti et al. 2003). The expression of MMPs is usually low in tissues and 
increases when remodeling is required. MMP3, like many other MMPs, is first 
secreted as a proenzyme and requires further activation. MMP3 can degrade 
collagens and matrix proteins such as laminin and proteoglycan (Chen et al. 
2014). More importantly, MMP3 has the ability to activate other MMPs (e.g. 
MMP1, MMP9, MMP13) amplifying the proteolytic effect (Leong et al. 2010; 
Chen et al. 2014). The activity of MMPs is strictly controlled by tissue 
inhibitors of MMPs (Brew et al. 2000). MMP3 is associated with different 
diseases that include OA (Leong et al. 2010; Chen et al. 2014), myocardial 
infarction and morbidity after the infarction (Wang et al. 2011; Abd El-Aziz & 
Mohamed, 2016), as well as malignancies (Morrison et al. 2009).  
The expression of MMP3 has been found to be increased in OA compared 
with healthy controls and the level of MMP3 correlates positively with cartilage 
damage (Lohmander et al. 1993; Fernandes et al. 2002) (Lohmander et al. 
1993). Furthermore, MMP3 was highly expressed in the synovium, which 
suggests an important role of the synovium in MMP3 production and 
subsequent cartilage damage. Among other MMPs and inflammatory mediators, 
MMP3 is expressed in the damaged superficial cartilage layer in OA (Tetlow et 
al. 2001). Inflammation and adipokines can promote the production of MMP3 
(Conde et al. 2011; Yang et al. 2013). It has been demonstrated that immobili-
sation increases MMP3 levels and mobilisation can decrease the level of MMP3, 
thus combating cartilage deterioration (Leong et al. 2010). In conclusion, 
MMP3 is associated with cartilage damage in OA and might prove to be an 
early biomarker of OA and reflect disease severity. However, further research is 
needed in order to clarify which the clinical relevance of MMP3 in OA. 
 
 
2.4.4 Metabolomic profiling of osteoarthritis 
Metabolomics is a novel methodology for assessing low-molecular weight 
molecules (<1.5 kDa) in a biological system at a specific point of time. The 
recent and most demanding challenge in systems biology is to incorporate 
genomics, transcriptomics, proteomics and metabolomics to provide a better 
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understanding of cellular biology. Metabolomics focuses on identification and 
quantification of small intermediary molecules and products of metabolism, the 
metabolome. The metabolome is the terminal downstream product of the 
genome and consists of the total amount of low-molecular weight molecules in 
an organism that are required for maintaining normal function in a specific 
physiological state. These metabolites include amino acids, peptides, carbo-
hydrates, vitamins, thiols, lipids, nucleic acids and fatty acids (Zhang et al. 
2012). Therefore, the metabolome represents a real time functional portrait of a 
living organism.  
Several detection methods that are used to quantify changes in the concent-
rations of endogenous metabolites include, but are not limited to, 1H-nuclear 
magnetic resonance, 13C-nuclear magnetic resonance spectroscopy, gas-chro-
matography-mass spectrometry, direct infusion-mass spectrometry, gas chro-
matography-flame ionization detection and liquid chromatography-mass 
spectrometry (Roberts & Sindhu, 2009).  
Two fundamentally distinct approaches can be taken to analyse the biofluids 
or tissues: targeted and non-targeted metabolomics (Nobeli & Thornton, 2006). 
For targeted metabolomics, quantitative values for only a preselected set of 
known metabolites are determined (Klein & Shearer, 2016). Also, internal 
standards must be used to calibrate sample concentrations by adding reference 
substances at known concentrations in order to obtain accurate and valid results. 
However, non-targeted analysis is the comprehensive analysis of all detectable 
metabolites in a sample. This includes a large number of unknown metabolites. 
Both approaches have pros and cons and the choice of the method depends on 
the study objectives (Christians et al. 2011).  
Metabolomic profiling of OA is a novel approach for obtaining insights into 
the pathophysiological mechanisms that drive OA as well as for detecting new 
biomarkers. In recent years the field of metabolomic research is growing rapidly 
and scientists are sensing the potential of this methodology. There are several 
studies that have adopted this approach to analyse OA (Lamers et al. 2005; 
Zhang et al. 2014, 2015). Metabolomics is highly needed in the field of OA 
because of the heterogeneity of the disease and the recognition that no single 
biomarker can fully describe the pathological processes involved in the OA 
(Bay-Jensen et al. 2016). A study investigating the metabolite profile of urine in 
OA patients and controls found distinct changes in the profile of OA subjects 
and the profile was associated with radiographic severity (Lamers et al. 2005). 
Another study demonstrated that the serum ratios of valine and leucine to 
histidine were related to knee OA, which suggested the use of branched-chain 
amino acids as potential biomarkers (Zhai et al. 2010). In addition, pertur-
bations of lipid metabolism have been described in OA (Adams et al. 2012; 
Zhang et al. 2014). 
Acylcarnitines are the intermediates of the fatty acid β-oxidation process.  
L-carnitine is required to transport activated long-chain fatty acids from the 
cytosol into the mitochondrion, where fatty acid oxidation takes place. Inside 
the cell fatty acids are activated by esterification with co-enzyme-A. 
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Acylcarnitines are produced via transfer of a fatty acyl-Co-enzyme-A to L-car-
nitine by carnitine transferases. After being transported through the mito-
chondrial membrane, the acyl-co-enzyme-A is converted to acylcarnitines by 
carnitine palmitoyltransferase 1 (CPT-1). CPT-1 is one of the most important 
regulators of long-chain fatty acid oxidation (McGarry et al. 1977). After being 
transported into the mitochondrion matrix, CPT-2 reconverts acylcarnitines 
back into free carnitine and long-chain acyl-co-enzyme-A that can then be 
oxidized (Ramsay et al. 2001). Acylcarnitines are transported through the cell 
membrane and circulate in plasma. The physiological role of acylcarnitine 
efflux to plasma is unclear. However, acylcarnitine formation prevents Co-
enzyme-A trapping, thus enforcing continuation of Co-enzyme-A dependent 
metabolic processes (Lopaschuk et al. 1994). Acylcarnitines might also play a 
role in the detoxification process since they are found in urine and bile 
(Chalmers et al. 1984; Mueller et al. 2003). While the physiological role of 
plasma acylcarnitines remain to be elucidated, the level of acylcarnitines has 
been associated with several diseases including diabetes (Mihalik et al. 2010), 
encephalopathy (Murphy et al. 2007) and OA (Zhang et al. 2014) among others. 
Recent evidence suggests that acylcarnitines might be associated with activation 
of the pro-inflammatory signalling pathway (Rutkowsky et al. 2014). A serum 
assay of acylcarnitines has been performed for screening of genetic disorders of 
oxidation of fatty acid enzymes, which typically result in accumulation of 
acylcarnitines due to poor co-ordination between β-oxidation and the 
tricarboxylic acid cycle (Pourfarzam & Zadhoush, 2013). A nested case-control 
study has found that long-chain acylcarnitines predicted cardiovascular 
mortality in dialysis patients (Kalim et al. 2013). Another study found 
independent association between acylcarnitines and heart failure (Ahmad et al. 
2016). In addition, the plasma level of acylcarnitines has been found to be 
associated with aortic stiffness in coronary artery disease patients (Paapstel et 
al. 2016). There are few small studies investigating the role of acylcarnitines in 
OA. A case-only study with 80 end-stage OA patients found that the patients 
can be divided into two distinct groups according to levels of acylcarnitines 
(Zhang et al. 2014). One of the groups had higher prevalence of hypertension, 
which might suggest that the CVD risk in these groups was different. Thus, 
acylcarnitines are associated with different disease groups and might provide 
insights into the pathologies involved in pathogenesis of the disease at a cellular 
level.  
So far the disease-modifying treatment does not exist for OA and one of the 
pitfalls of developing new treatment is due to difficulties in accurate assessment 
of therapy response using radiographic techniques. Thus, there is urgent need 
for novel biomarkers that could describe disease status, prognosis and treatment 
response confidently in these patients. Metabolomics is close to ideal method 
for finding novel biomarkers. Moreover, studies published so far suggest that 
acylcarnitines might provide insights into the pathogenesis of OA and CVD. 
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2.5 Summary of the Literature 
OA is a complex disease but still lacks a clear understanding of etiopatho-
genesis. There are several pieces of evidence suggesting increased CVD risk for 
OA patients, however the precise mechanisms are largely unknown. Only a few 
inconclusive studies with discordant results have investigated the association 
between OA and arterial stiffness, which is independent CVD risk factor. 
Another possible link between OA and CVD is obesity that promotes systemic 
low-grade inflammation and dysbalance in the level of adipokines. Therefore, 
further research is requiered to clarify the role of adipokines in OA and their 
potential as clinical biomarkers. In addition, there is no consensus on how MetS 
and OxS are linked to OA. The potential protective role of HDL-cholesterol and 
detrimental effects of triglycerides and LDL-cholesterol in OA needs to be 
elucidated. Furthermore, being able to detect changes in the low molecular 
weight metabolites might provide valuable information about the pathogenesis 
of OA, which helps to develop better diagnostic and prognostic biomarkers.  
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3. AIMS OF THE THESIS 
The general aim of the thesis was to analyze arterial stiffness and metabolic 
biomarkers in end-stage osteoarthritis patients in comparison to controls. The 
current thesis was focused to explore the role of vascular function in osteo-
arthritis and to search new promising biomarkers for early diagnosis and disease 
course prediction. 
 
Specific aims:  
1. To measure arterial stiffness in osteoarthritis patients in comparison with 
asymptomatic controls and to assess the relationship between arterial 
stiffness and osteoarthritis severity. 
2. To determine the levels of adipokines (leptin, adiponectin) and matrix 
metalloproteinase 3 in relation to osteoarthritis severity and arterial stiffness 
in end-stage osteoarthritis patients and in controls. 
3. To assess the impact of metabolic syndrome and oxidative stress for osteo-
arthritis patients and for controls. 
4. To determine the impact of acylcarnitines on osteoarthritis severity and on 
arterial stiffness in patients with end-stage osteoarthritis and in controls. 
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4. SUBJECTS AND METHODS 
4.1 Subjects 
4.1.1 Osteoarthritis patients 
The study population included a total of 70 patients with end-stage knee and hip 
OA (n=48, n=70, n=55, n=70 in Papers I–IV, respectively). The study 
participants were prospectively recruited from the Department of Orthopaedic 
Surgery, Tartu University Hospital, Estonia, in 2014-2016. Only patients with 
primary OA were included according to the American College of Rheumatology 
criteria for knee and hip OA (Altman et al. 1986, 1991). The exclusion criteria 
were posttraumatic OA, infectious and endocrine related arthropathy, any acute 
or chronic inflammatory disease, malignancy, renal insufficiency (estimated 
glomerular filtration rate (eGFR) < 60ml/min/1.73m2), cardiac arrhythmia, 
clinically significant heart failure, valvular disease, diabetes. The presence of 
these conditions was determined based on interview with the study participant, 
clinical examination, blood tests and medical database. 
 
 
4.1.2 Age- and gender-matched controls 
A total of 82 age- and gender matched subjects (n=49, n=70, n=55, n=82 in 
Papers I–IV, respectively) were identified using assistance from local family 
physicians. The exclusion criteria for the control group were (based on inter-
views, clinical examinations and blood tests): any concomitant acute or chronic 
inflammatory disease, a visit to family practitioner due to hip or knee joint 
complaints, any persistent knee or hip joint pain, diabetes, symptomatic 
coronary artery disease, cardiac arrhythmia, cerebrovascular or peripheral artery 
disease, malignancies and renal insufficiency. 
 
 
4.2 Study design and protocol 
The medical history and lifestyle factors were recorded using a self-completed 
questionnaire and interview. Blood samples were collected between 07:00 and 
11:00 after an overnight fast and abstinence from tobacco, coffee and alcohol. 
The height and weight of the patients were recorded and BMI was calculated. 
Waist circumference was measured with a tape at the end of a normal expirium 
at the narrowest part between the iliac crest and the lowest rib. HHS and HSS 
Knee score were assessed. The study participants were examined after at least 
10 minutes of rest in a supine position in a quiet, temperature controlled room. 
Next, peripheral BP and PWV were measured and PWA was performed. 
Written informed consent was obtained from all study participants. The study 
was approved by the Ethics Committee on Human Research of the University of 
Tartu.  
32 
4.3 Methods 
4.3.1 Measurement of osteoarthritis severity 
Standard weight-bearing anteroposterior radiographs were taken from the hip 
and knee joint. The radiographic severity of OA was assessed using the 
Kellgren-Lawrence grading system (Kellgren & Lawrence, 1957). The radio-
graphs were evaluated independently by two observers who were blinded to the 
clinical data and a consensus score was used. Intraclass correlation coefficient 
was used to assess consistency among the raters. The values of intraclass 
correlation coefficient under 0.75 are considered poor to moderate, over 0.75 
good and over 0.90 reasonable for clinical measurements (Portney & Watkins, 
2009). In addition, HHS (Harris, 1969) and HSS Knee score (Insall et al. 1976) 
were used as physician reported outcome measures for the hip and knee OA 
patients, respectively, and for the controls. 
 
 
4.3.2 Analysis of biochemical markers 
Peripheral venous blood samples were collected (into serum separator tubes BD 
SST IITM Advance) and centrifuged at room temperature 30 minutes after 
collection. The serum was pipetted into Eppendorf tubes and stored at –70°C 
until analysis. The serum levels of triglycerides, total cholesterol, LDL-
cholesterol, HDL-cholesterol, white blood cell count, high-sensitivity C-reactive 
protein (hs-CRP), serum creatinine, and eGFR were measured, using standard 
laboratory methods in the local clinical laboratory, with automated analyzers.  
Serum adiponectin levels were measured using an enzyme-linked immuno-
sorbent assay (ELISA) (Human Total Adiponectin/Acrp30 Immunoassay, R&D 
Systems Europe, Abingdon, UK). Human Total MMP3 Immunoassay kits 
available from R&D systems a Bio-Techne brand (catalogue number DMP 300) 
were used for quantitative determination of human active and promatrix 
metalloproteinase 3 (total pro-MMP3) concentrations. The level of serum leptin, 
resistin, C-peptide and insulin was measured using Evidence Investigator™ 
Metabolic Syndrome Array1, based on the sandwich chemoluminescent 
immunoassay (Randox Laboratories Ltd METS1 catalogue number EV 3755). 
The core technology is the Randox Biochip which contains an array of discrete 
test regions of immobilized antibodies specific for different biomarkers of 
MetS. The light signal generated from each of the test regions on the biochip is 
detected using the digital imaging technology. Insulin resistance was calculated 
from glucose and insulin levels, using updated nonlinear homeostasis model 
assessment estimated insulin resistance (HOMA2 IR) (Levy et al. 1998), which 
takes account of variations in hepatic and peripheral glucose resistance. 
The total peroxide concentration (TPX) of the samples was determined using 
the OXYSTAT Assay Kit Cat. No BI-5007 (Biomedica Gruppe, Biomedica 
Medizinprodukte GmbH & Co Kg, Wien). Peroxide concentration was 
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determined by the reaction of biological peroxides with peroxidase and the 
subsequent colour reaction using TMB as the substrate. After addition of a stop 
solution, the coloured liquid was measured. A calibrator was used to calculate 
the concentration of circulating biological peroxides in the sample. TAC was 
measured applying an automated measurement method (Erel, 2004). In TAC 
measurement, a hydroxyl radical is produced. The ferrous ion solution in 
reagent 1 was mixed with H2O2 in reagent 2. Sequentially produced radicals 
include the brownish-coloured dianisidinyl radical cation. The antioxidative 
effect of the sample on potent free radical reactions was used to determine TAC. 
The percentage of the ratio of total plasma peroxide concentration to plasma 
TAC was accepted as oxidative stress index (OSI), which is an indicator of 
OxS. Commercially available ELISA kits were used to determine serum 
oxidized low-density lipoproteins (oxLDL) (Mercodia AB, Uppsala Sweden; 
catalogue number 10-1143-01) and myeloperoxidase (MPO) (Biocheck, Foster 
City, CA; catalogue number BC 1129). 
 
 
4.3.3 Targeted analysis of metabolites 
Serum for detection of metabolites was collected into plain tubes (Plain BD 
Vacutainer® Tubes). Samples were centrifuged for 60 minutes and the 
supernatant was pipetted into Eppendorf tubes and frozen at –70°C until 
analysis. The levels of metabolites in the serum were determined using the 
AbsoluteIDQ™ p180 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria) 
according to the manufacturer’s instructions. The assay procedures have been 
described in detail previously (Nkuipou-Kenfack et al. 2014). The validated 
assay allows comprehensive identification and quantification of 186 endo-
genous metabolites including 40 acylcarnitines, 14 lysophosphatidylcholines, 76 
phosphatidylcholines, 19 biogenic amines, 21 amino acids, 15 sphingomyelins 
and the sum of hexoses from 10 μl of serum. The total number of carbons and 
double bonds present in the lipid fatty acid chains are denoted by C x:y, where x 
indicates the number of carbons and y indicates the number of double bonds. 
Glycerophospholipids are further differentiated according to the presence of 
ester (a) and ether (e) bonds in the glycerol moiety. Double letters (aa = diacyl, 
ae = acyl–alkyl) indicate that two glycerol positions are bound to the fatty acid 
residue, while a single letter (a = acyl or e = alkyl) indicates a bond with only 
one fatty acid residue. Identification and quantification of the metabolites was 
done using multiple reaction monitoring according to internal standards. 
Calculation of metabolite concentration was automatically performed using the 
MetIDQ™ software package integrated into the AbsoluteIDQ kit. The 
concentrations of metabolites were calculated in μM.  
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Table 1. Acylcarnitines that can be quantified with the AbsoluteIDQ p180 kit 
(http://www.biocrates.com/images/ListofMetabolites_p180.pdf). 
Acylcarnitines 
C0 Carnitine C10:1 Decenoylcarnitine 
C2 Acetylcarnitine C10:2 Decadienylcarnitine 
C3 Propionylcarnitine C12 Dodecanoylcarnitine 
C3:1 Propenoylcarnitine C12:1 Dodecenoylcarnitine 
C3-OH Hydroxypropionyl-
carnitine 
C12-DC Dodecanedioylcarnitine 
C4 Butyrylcarnitine C14 Tetradecanoylcarnitine 
C4:1 Butenylcarnitine C14:1 Tetradecenoylcarnitine 
C4-OH (C3-DC) Hydroxybutyryl-carnitine C14:1-OH Hydroxytetradecenoylcarnitine 
C5 Valerylcarnitine C14:2 Tetradecadienylcarnitine 
C5:1 Tiglylcarnitine C14:2-OH Hydroxytetradecadienylcarnitine 
C5:1-DC Glutaconylcarnitine C16 Hexadecanoylcarnitine 
C5-DC (C6-OH) Glutarylcarnitine 
(Hydroxyhexanoyl-
carnitine) 
C16:1 Hexadecenoylcarnitine 
C5-M-DC Methylglutaryl-carnitine C16:1-OH Hydroxyhexadecenoylcarnitine 
C5-OH (C3-DC-M) Hydroxyvaleryl-carnitine 
(Methylmalonyl-carnitine) 
C16:2 Hexadecadienylcarnitine 
C6 (C4:1-DC) Hexanoylcarnitine 
(Fumarylcarnitine) 
C16:2-OH Hydroxyhexadecadienylcarnitine 
C6:1 Hexenoylcarnitine C16-OH Hydroxyhexadecanoylcarnitine 
C7-DC Pimelylcarnitine C18 Octadecanoylcarnitine 
C8 Octanoylcarnitine C18:1 Octadecenoylcarnitine 
C9 Nonaylcarnitine C18:1-OH Hydroxyoctadecenoylcarnitine 
C10 Decanoylcarnitine C18:2 Octadecadienylcarnitine 
 
 
4.3.4 Measurement of arterial stiffness and central 
haemodynamics 
Peripheral BP was measured using a digital oscillometric device (A&D  
UA-767; A&D Company Ltd., Tokyo, Japan) and the mean of three readings 
was recorded. Mean arterial pressure (MAP) was obtained by integration of the 
radial pressure waveform using the SphygmoCor software (SCOR Px, 7.0; 
AtCor Medical, Sydney, Australia).  
Pulse wave velocity was determined from electrocardiogram (ECG)-gated 
sequential recordings of the carotid and radial or femoral pulse waveforms 
(SphygmoCor, AtCor Medical, Sydney, Australia) using an arterial tonometer 
(SPT-301B, Millar Instruments, USA). The R-wave in ECG was used as the 
reference in determining the travel time of the pulse wave between the 
recording sites. The PWV was automatically calculated by the Sphygmocor 
software as the ratio of the distance between the measuring sites to the transit 
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time (Townsend et al. 2015). For calculating the cf-PWV, the distance from the 
suprasternal notch over the umbilicus to the femoral artery minus minus the 
distance from suprasternal notch to the carotid artery was used. For calculating 
cr-PWV, the distance from the suprasternal notch to the radial artery measuring 
site carotid arterial length was obtained. Sequential recording was done over an 
approximate 20 sec of time with atleast 15 waveforms at one measuring site. All 
PWV measurements were made in duplicate and mean values were used in 
analysis. Recordings with a variation of more than 5 heart beats per minute were 
excluded. 
Pulse wave analysis was employed for measuring central haemodynamics 
with the Sphygmocor device (version 7.1, AtCor Medical, Sydney, Australia). 
At least 15 sequential waveforms were measured at the subject’s left wrist with 
a high fidelity micromanometer (SPT-301B, Millar Instruments, USA). Corres-
ponding ascending aortic waveforms were then generated using a transfer 
function to calculate AIx and central haemodynamics (Pauca et al. 2001). AIx 
was defined as the difference between the second and the first systolic peaks of 
the central aortic wave, which was expressed as the percentage of central pulse 
pressure (Laurent et al. 2006). The AIx was adjusted automatically by means of 
the Sphygmocor software for 75 heart beats per minute (AIx@75).  
In addition, arterial stiffness was measured using the diastolic part of the 
cardiac cycle. The pulse waveform was recorded from the right radial artery 
with a Cardiovascular Profiling Instrument (HDI/Pulse Wave CR-2000; 
Hypertension Diagnostics Inc, Eagan, USA) which measures large and small 
artery elasticity during 30 sec of recording. The subject’s hand was supported 
with a wrist stabilizer for minimal movements and optimal positioning. The 
mean of two recordings was used for analysis. 
 
 
4.3.5 Statistical analysis 
Statistical analysis was performed using the Statistical Package of the Social 
Science software for Windows, version 22.0 (SPSS, Chicago, IL, USA). Cate-
gorical variables were expressed in percentages. Continuous variables were 
presented as mean ± SD, or as median and interquartile ranges. The Shapiro–
Wilk test was employed to ascertain whether variables were normally distri-
buted (Papers I–IV). Two tailed Student’s t-test was used for comparing the 
means of normally distributed data and the Mann–Whitney U-test was used for 
non-parametric data. 
The calculation of intraclass correlation coefficient is based on absolute 
agreement and mixed model and single measures were used. Pearson’s corre-
lation coefficient and Spearman’s rho were used to identify associations bet-
ween continuous variables within the study groups. The Chi-square test or 
Fischer’s exact test was used to compare group proportions.  
Multiple linear regression analysis, using a forward and backward stepwise 
variable selection procedure, was performed to investigate independent 
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associations between variables. Cf-PWV (Papers I, II, IV) and ox-LDL (Paper 
III) were used as the dependent variables in multiple regression analysis. The 
variables inserted into the model were selected from univariate correlation 
analyses and previous observations. Analysis of covariance was used to adjust 
for BMI (Papers I, II, III), MAP (Paper I, II) and age (Paper I, II). Statistical 
significance was defined as p<0.05. The Benjamini-Hochberg procedure was 
used to account for false discovery rate at the of 0.05 level (Benjamini & 
Hochberg, 1995) (Papers III, IV). 
Principal component analysis (PCA) was performed to reduce the large 
number of correlated metabolites to fewer uncorrelated components for the OA 
patients and the controls. Varimax rotation was used to identify interpretable 
factors. Only the factors that explained at least 5% of total variance were 
included in further analysis. Only the metabolites with absolute factor loadings 
of at least 0.50 were reported as the components of a given factor in order to 
avoid false discoveries. Next, for each subject, factor scores (weighted sum of 
the standardized metabolites within a given factor, weighted on the factor loading 
for each individual metabolite) were calculated and included in analysis. 
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5. RESULTS 
 5.1 Arterial stiffness in osteoarthritis patients and  
in controls (Papers I, II) 
Baseline characteristics of the study groups 
The baseline characteristics of the OA and control groups are presented in 
Table 2. There was no significant difference in age or male to female ratio 
between the study groups. The level of BMI and the W/H-ratio were signi-
ficantly higher and the HHS and HSS Knee scores were lower in the OA group. 
Smoking status did not differ significantly between the study groups.  
 
Table 2. General parameters of the osteoarthritis patients and the controls. 
Variable Osteoarthritis (n=70) Controls (n=70) p-value 
Age (years) 62 ± 70 60 ± 70 0.066 
Male/Female (n) 35 / 35 36 / 34 0.866 
BMI (kg/m2) 28 ± 30 26 ± 30 0.001 
Waist circumference (cm) 96 ± 90 88 ± 11 <0.001 
Hip circumference (cm) 104 ± 700 02 ± 60 0.033 
W/H- ratio 0.92 ± 0.08 0.87 ± 0.09 0.001 
Smoking (n, %) 0.127 
Current smoker 15 (22) 8 (11) 
Former smoker 4 (6) 9 (13) 
Non-smoker 50 (72) 53 (76) 
Involved joint (n) 
Hip 41 0 
Knee 29 0 
HHS 37 (32–48) 100 (100–100) <0.001 
HSS Knee score 62 (49–65) 100 (100–100) <0.001 
 
Parameters of arterial stiffness in osteoarthritis patients and in controls 
The parameters of arterial stiffness and central hemodynamics are presented in 
Table 3. After adjusting for BMI and MAP, the level of cf-PWV was signi-
ficantly higher in the OA group compared with the controls. The level of small 
artery elasticity was significantly lower in the OA patients than in the control 
group. Also, MAP, peripheral BP and central BP were significantly higher in 
the OA group after adjusting for BMI. While in Paper I the level of AIx@75 
was significantly higher in the OA group, the difference in the level of AIx@75 
was not statistically significant in Paper II (p=0.078) involving a higher number 
of study participants. However, after adjusting for the gender proportions, the 
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AIx@75 was significantly higher in the OA group (p=0.033). There were no 
differences in large artery elasticity index between the study groups. 
 
Table 3. Hemodynamic parameters of the osteoarthritis patients and the controls. 
Variable Osteoarthritis patients (n=70) Controls (n=70) p-value 
Peripheral systolic BP (mmHg) 133 ± 180 126 ± 150 0.011 
Peripheral diastolic BP (mmHg) 81 ± 80 78 ± 70 0.014 
Central systolic BP (mmHg) 125 ± 170 118 ± 150 0.014 
Central diastolic BP (mmHg) 82 ± 80 78 ± 80 0.019 
MAP (mmHg) 100 ± 110 95 ± 10 0.010 
Heart rate (bpm) 64 ± 11 61 ± 70 0.042 
AIx@75 (%) 25 ± 90 22 ± 11 0.078 
cf-PWV (m/s) 9.1 ± 2.2 8.2 ± 1.5 0.007a 
C1 (ml/mmHg×100)  12.8 ± 4.40 14.1 ± 5.00  0.119 
C2 (ml/mmHg×100)  4.2 ± 3.6 6.0 ± 2.7  0.002 
All variables are adjusted for BMI 
a- adjusted for mean arterial pressure 
 
In univariate correlation analysis the level of serum urea was positively 
correlated with cf-PWV and with central systolic BP (Figure 1 and Figure 2) as 
reported in Paper I. There were no association between parameters of arterial 
stiffness and urea in the control group.  
 
 
 
Figure 1. The association between cf-PWV and serum urea level (rho = 0.290, p = 0.046) 
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Figure 2. The association between central systolic pressure and serum urea level 
(rho = 0.318, p = 0.029) 
 
In multiple regression analysis (Table 4), where cf-PWV was set as the dependent 
variable, age (p < 0.001), MAP (p = <0.001) and OA status (p = 0.029) were 
found to be independent predictors (Paper I). 
 
Table 4. Multiple regression analysis with carotid-femoral pulse wave velocity as 
dependent variable (adjusted R2=0.48). 
Variable Regression coefficient Beta SE p- value 
Constant –6.68   <0.001 
Age 0.15 0.53 0.02 <0.001 
MAP 0.07 0.36 0.01 <0.001 
OA status 0.74 0.17 0.33 0.029 
Urea –1.20 –0.09 0.10 0.233 
 
In addition, a significant positive association was found between OA radio-
graphic Kellgren-Lawrence grade and cf-PWV (Figure 3B) (Paper II). The 
association was further analyzed separately in the hip and knee subgroups.  
Cf-PWV was set as the dependent variable in the hip OA patient group, and OA 
grade, age, MAP and hs-CRP remained significant independent predictors 
(Table 5a). In the knee OA group, OA grade was not an independent predictor 
of cf-PWV after adjusting for the W/H-ratio and age (Table 5b).  
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Figure 3. (A) Matrix metalloproteinase 3 levels for different osteoarthritis severity 
scores. (B) Boxplot describing cf-PWV in different groups of osteoarthritis severity.  
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Table 5a. Multiple regression analysis with cf-PWV as the dependent variable for the 
hip OA patients (adjusted R2=0.655, p<0.001). 
Variable B Std Error Beta t p- value 
Constant –8.487 2.445  –3.471 0.001 
OA grade 0.739 0.332 0.219 2.228 0.033 
Age 0.125 0.029 0.422 4.302 <0.001 
MAP 0.079 0.016 0.477 4.880 <0.001 
hsCRP –0.433 0.170 –0.246 –2.543 0.016 
Table 5b. Multiple regression analysis with cf-PWV as the dependent variable for the 
knee OA patients (adjusted R2=0.351, p=0.003). 
Variable B Std Error Beta t p- value 
Constant –10.450 5.357  –1.951 0.062 
Age 0.164 0.047  0.556 3.492 0.002 
W/H-ratio 11.326 5.345  0.344  2.119 0.044 
OA grade  –0.227 0.695 –0.055 –0.327 0.746 
 
5.2 Adipokines, matrix metalloproteinase 3 and arterial 
stiffness in osteoarthritis patients and in controls (Paper II) 
The levels of leptin, WBC, hsCRP and urea were higher, and the levels of 
adiponectin and HDL-cholesterol were lower for the patient group (Table 6). 
However, after correcting for BMI, the difference in hsCRP and platelet count 
was no longer significant and the difference in adiponectin had borderline 
significance. 
Table 6. Metabolic markers for the osteoarthritis and control groups. 
Variable Osteoarthritis  patients (n=70) Controls (n=70) p-value 
Triglycerides (mmol/l) 1.6 ± 1.2 1.4 ± 0.8 0.249 
LDL- cholesterol (mmol/l) 4.0 ± 0.9 3.9 ± 1.0 0.630 
HDL- cholesterol (mmol/l) 1.5 ± 0.4 1.7 ± 0.5 0.026 
Total cholesterol (mmol/l) 5.8 ± 1.1 5.8 ± 1.2 0.892 
hsCRP (mg/l) 1.89 ± 1.14 1.42 ± 0.96 0.093 
eGFR (ml/mg/1.73m2) 83 ± 15 83 ± 12 0.991 
Urea (mmol/L) 6.0 ± 2.0 5.2 ± 1.2 0.017 
White blood cells (109 / l) 6.5 ± 1.4 5.7 ± 1.9 0.010 
Platelets (109 / l) 243 ± 570 227 ± 550 0.123 
MMP-3 (ng/ml) 14.1 ± 6.54 10.9 ± 5.94 0.004 
Adiponectin (ng/ml) 8131 ± 5681 9664 ± 3897 0.066 
Leptin (ng/ml) 03.7 ± 5.14 2.20 ± 1.85 0.022 
All variables are adjusted for BMI 
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In addition, Kellgren-Lawrence grade correlated positively with MMP3 
(Figure 3A) and inversely with leptin. However, these associations did not 
remain significant after adjustment for potential confounders. Furthermore, we 
found that adiponectin was correlated with C1 and AIx@75 (Figure 4). In the 
model where adiponectin was set as the dependent variable, neither C1 nor AIx 
was an independent predictor when the potential confounders were included.  
 
Figure 4. Associations of adiponectin with (A) augmentation index (r=0. 293, p=0.006) 
and (B) large artery elasticity index (r=–0.249, p=0.003). 
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5.3 Oxidative stress and metabolic syndrome in 
osteoarthritis patients and in healthy controls (Paper III) 
General parameters of osteoarthritis patients and controls 
A total of 110 participants, who were divided into two groups according to 
presence of OA, were evaluated and the general parameters are presented in 
Table 7. The study groups did not differ significantly with regard to the age, 
gender proportions, BMI or the W/H-ratio. The mean age of the OA patients 
was 63 ± 7 years and the proportion of male subjects was 53%. The mean age of 
the controls was 61 ± 8 years and the proportion of males was 51%. Thirty-five 
patients had predominantly hip OA and 20 patients had knee OA. The pro-
portion of the smoking status was not significantly different across the study 
groups (Table 7). The study groups did not differ significantly with regard to 
waist circumference, fasting glucose level, triglycerides level, HDL level or 
peripheral systolic BP. 
The subjects in the OA group had significantly higher insulin and C-peptide 
levels and their HOMA2 IR levels were higher with borderline significance 
(p=0.050). The level of resistin was lower in the OA group with borderline 
significance (p=0.056). The differences in triglycerides, HOMA2 IR and insulin 
were no longer significant after adjusting for BMI and accounting for multiple 
testing. The level of TPX and OSI was significantly higher in the OA group 
while total antioxidant capacity (TAC) was significantly lower in this group. 
MPO and oxLDL did not differ significantly between the study groups. 
The prevalence of MetS was 9% in the control group and 20% in the OA 
group (p=0.105). The proportions of the MetS components in the OA and 
control groups are presented in Figure 5. 
 
Table 7. General and metabolic parameters of the osteoarthritis patients and the controls. 
Variable Osteoarthritis 
(n=55) 
Controls  
(n=55) 
p-value 
Age (years) 63 ± 70 61 ± 80 0.301 
Male/Female (n) 29 / 26 28 / 27 0.849 
BMI (kg/m2) 27 ± 30 26 ± 30 0.112 
Waist circumference (cm) 96 ± 10 91 ± 12 0.163a 
W/H- ratio 0.92 ± 0.08 0.89 ± 0.09 0.096 
HSS Knee score 54 (49–65) 100 (99–100) 0.001 
HHS 37 (32–48) 100 (100–100) 0.001 
OA severity 3 (3–4) N/A  
Smoking (n, %)   0.280 a 
Current smoker 11 (20) 7 (13) 
Former smoker 3 (6) 9 (16) 
Non-smoker 41 (75) 39 (71) 
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Variable Osteoarthritis 
(n=55) 
Controls  
(n=55) 
p-value 
Hypertension (%) 55 38 0.085 
Peripheral systolic BP (mmHg) 134 ± 180 129 ± 180 0.353 a 
LDL-cholesterol (mmol/L) 3.9 ± 0.9 3.9 ± 1.0 0.899 a 
Triglycerides (mmol/L) 1.4 (1.03–1.91 1.2 (0.83-1.57) 0.280 a 
HDL-cholesterol (mmol/L) 1.5 ± 0.5 1.7 ± 0.5 0.290 a 
Fasting glucose (mmol/) 5.8 ± 0.7 5.7 ± 0.4 0.704 a 
Insulin (pmol/L) 52 (35–72) 41 (32–53) 0.353 a 
HOMA2 IR 1.0 (0.7–1.4) 0.8(0.6–1.0 0.420 a 
C-peptide (ng/ml) 1.6 (0.94–2.47) 0.9 (0.46–1.42) 0.003 a 
Resistin (ng/ml) 2.6 ± 0.9 3.3 ± 1.8 0.054 a 
oxLDL (U/L) 78 ± 22 73 ± 24 0.578 a 
MPO (ng/ml) 37 ± 20 42 (22–55) 0.463 a 
TPX (µmol/L) 357 (250–612) 286 (168–442) 0.011 a 
TAC (mmol trolox 
equivalent/L) 1.49 ± 0.27 1.66 ± 0.27 0.008
 a 
OSI (%) 25 (17–51) 18 (11–28) 0.002 a 
ACEI (n, %) 5 (9) 12 (22) 0.112 
ARB(n, %) 7 (4) 2 (13) 0.161 
Aspirin (n, %) 2 (4) 3 (6) 1.0 
Ca channel blocker (n,%) 6 (11) 1 (2) 0.113 
Beta-blocker (n, %) 5 (9) 6 (11) 1.0 
Diuretics (n, %) 7 (4) 1 (2) 0.363 
Statins (n, %) 1 (2) 0 (0) 1.0 
a- the p-value has been adjusted for BMI and multiple testing 
 
 
 
 
 
Figure 5. The count 
of metabolic factors 
(hypertension, cent-
ral obesity, high tri-
glyceride level, low 
HDL-cholesterol le-
vel, high fasting glu-
cose level) per study 
participant among 
the osteoarthritis 
group and the control 
group. 
Table 7. Continuation 
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Associations between metabolic markers and osteoarthritis 
The associations between OA severity, metabolic factors and OxS parameters 
are presented in Table 8. In univariate analysis, waist circumference, LDL-
cholesterol, insulin, HOMA2 IR and oxLDL were positively associated with 
OA severity. After adjusting for the potential confounders (BMI, age, gender) 
and accounting for multiple testing, OA severity was associated with LDL-
cholesterol and oxLDL. There was no significant association between OA 
severity and W/H-ratio (Rho=0.24, p=0.087) in the present study. 
 
Table 8. Associations between osteoarthritis severity, components of metabolic 
syndrome, glucose metabolism and oxidative stress in osteoarthritis patients. 
 OA severity 
 Rho p-value BMI and age 
adjusted  
p-value 
BMI, age and 
 gender adjusted  
p-value a 
Metabolic syndrome 
components   
  
Waist circumference 0.31 0.022 0.076* 0.119* 
Peripheral systolic BP  0.20 0.135 0.107 0.078 
Triglycerides 0.22 0.107 0.111 0.155 
HDL-cholesterol –0.20 0.153 0.517 0.522 
Fasting glucose 0.06 0.681 0.821 0.412 
Dyslipidemia     
LDL-cholesterol 0.40 0.003 0.017 0.007 
Glucose metabolism markers   
HOMA2 IR 0.29 0.033 0.056 0.081 
Insulin 0.28 0.039 0.141 0.165 
C-peptide 0.23 0.089 0.283 0.265 
Oxidative stress markers   
OxLDL 0.37 0.006 0.019 0.022 
MPO –0.16 0.260 0.863 0.492 
TPX –0.19 0.160 0.133 0.226 
TAC 0.24 0.084 0.195 0.250 
OSI –0.25 0.062 0.077 0.154 
* waist circumference was not adjusted for BMI 
a- the p-values have been accounted for multiple testing 
 
In multiple regression analysis, OxLDL was independently associated with OA 
severity (p=0.040) and with MetS score (p=0.008) when BMI and smoking 
status were taken into account (Table 9). None of the components of MetS was 
significantly associated with oxLDL when they were entered into the model 
together with OA severity and BMI. 
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Table 9. Regression model with oxLDL as the dependent variable in osteoarthritis 
patients. 
Variable B Std Error Beta p- value 
Constant 17.91 25.00  0.477 
MetS score 6.51 2.36 0.36 0.008 
OA severity 8.51 4.04 0.25 0.040 
Smoking status 7.25 4.58 0.19 0.119 
BMI 0.68 0.91 0.10 0.458 
 
5.4 Medium- and long-chain acylcarnitines  
in osteoarthritis patients and in controls (Paper IV) 
Characteristics of the study population 
In Paper IV a total of 152 participants were evaluated (70 with OA vs 82 
controls). General, hemodynamic and biochemical variables are presented in 
Table 10. The study groups did not differ significantly in regard to age, male to 
female ratio, cr-PWV, LDL-cholesterol or fasting glucose levels. The levels of 
BMI, W/H-ratio, peripheral and central BP, cf-PWV and PWV-ratio were 
significantly higher in the patient group. In addition, inflammatory markers (hs-
CRP, WBC, TNF-α) were significantly higher in the OA group. After adjusting 
for gender ratio and BMI, the level of AIx@75 was significantly higher in the 
OA group (p=0.008). 
 
Table 10. General and hemodynamic parameters. 
Variable Osteoarthritis (n=70) 
Controls  
(n=82) 
p-value 
Age (years) 62 ± 70 61 ± 80 0.217 
Male/Female (n) 36 / 34 37 / 45 0.515 
BMI (kg/m2) 27.8 ± 3.20 26.0 ± 3.50 0.001 
Hypertension (n (%)) 33 (45) 11 (13) 0.001 
Peripheral systolic BP (mmHg) 134 ± 180 127 ± 160 0.013 
Peripheral diastolic BP (mmHg) 81 ± 80 78 ± 80 0.010 
Central systolic BP (mmHg) 126 ± 170 119 ± 160 0.011 
Central diastolic BP (mmHg) 82 ± 80 79 ± 90 0.011 
MAP (mmHg) 100 ± 110 95 ± 11 0.005 
HR (bpm) 64 ± 80 62 ± 80 0.041 
AIx@75 (%) 25 ± 90 22 ± 11 0.110 
cf-PWV (m/s) 9.3 ± 2.2 8.2 ± 1.7 0.001 
cr-PWV (m/s) 8.7 ± 1.1 8.6 ± 1.1 0.549 
PWV-ratio 1.07 ± 0.22 0.96 ± 0.19 0.001 
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Variable Osteoarthritis (n=70) 
Controls  
(n=82) 
p-value 
hs-CRP (mg/l) 1.9 ± 1.1 1.5 ± 1.2 0.014 
WBC (109/l) 6.5 ± 1.4 5.7 ± 1.9 0.001 
TNF-α (pg/ml) 7.5 ± 2.1 6.3 ± 1.9 0.001 
LDL-cholesterol (mmol/l) 4.0 ± 0.9 3.9 ± 1.1 0.804 
Triglycerides (mmol/l) 1.7 ± 0.8 1.4 ± 1.1 0.001 
HDL-cholesterol (mmol/l) 1.5 ± 0.5 1.7 ± 0.5 0.001 
Total cholesterol (mmol/l) 5.8 ± 1.1 5.7 ± 1.3 0.539 
Fasting glucose (mmol/l) 5.7 ± 0.7 5.7 ± 0.5 0.509 
 
The levels of acylcarnitines in the osteoarthritis patients and in the controls 
Table 11 presents the acylcarnitines derived from PCA. The levels of C10:1, 
C10:2, C12, C12:1, C14, C14:2, C14:1-OH, CPT1-ratio and total AC/C0 were 
found to be significantly lower in the OA group after adjusting for BMI and 
accounting for multiple testing. PCA determined 4 distinct components that are 
presented in Table 12. 
 
Table 11. Acylcarnitines in the osteoarthritis group and in the control group. 
Variable Osteoarthritis (n=70) 
Controls  
(n=82) 
p-value a 
C10:1 0.131 ± 0.069 0.151 ± 0.060 0.014 
C10:2 0.069 ± 0.011 0.072 ± 0.016 0.050 
C12 0.110 ± 0.045 0.135 ± 0.050 0.004 
C12:1 0.125 ± 0.049 0.140 ± 0.045 0.043 
C14 0.024 ± 0.006 0.027 ± 0.009 0.014 
C14:1 0.046 ± 0.023 0.054 ± 0.025 0.052 
C14:2 0.017 ± 0.007 0.021 ± 0.009 0.011 
C14:1-OH 0.013 ± 0.003 0.015 ± 0.004 0.004 
C14:2-OH 0.008 ± 0.002 0.008 ± 0.002 0.052 
C16 0.114 ± 0.024 0.107 ± 0.029 0.220 
C16:1 0.032 ± 0.009 0.032 ± 0.010 0.630 
C16:1-OH 0.013 ± 0.003 0.013 ± 0.003 0.236 
C18 0.053 ± 0.013 0.053 ± 0.015 0.807 
C18:1 0.143 ± 0.033 0.132 ± 0.036 0.088 
Total AC / C0 0.261 ± 0.065 0.320 ± 0.078 0.004 
CPT1 ratio 0.004 ± 0.001 0.005 ± 0.001 0.050 
All variables are adjusted for BMI and accounted for multiple testing. Concentrations of all 
acylcarnitines are presented as µM.  
a- Benjamini-Hochberg adjusted p-value 
Table 10. Continuation 
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Table 12. Principal component analysis for the osteoarthritis group. 
Factor Description Components Eigenvalue Variance 
(%) 
1 
Phosphatidyl-
cholines, 
 sphingomyelins 
Total PC ae, PC ae C40:3, Total SM, PC ae 
C36:2, PC ae C34:1, PC ae C36:1, Total SM-
OH, Total SM-non OH, SM C16:0, SM (OH) 
C22:2, PC ae C34:0, SM C16:1, SM (OH) 
C16:1, SM (OH) C14:1, PC ae C40:5, PC ae 
C40:6, SM (OH) C22:1, PC aa C32:3, PC aa 
C28:1, PC ae C40:2, PC ae C38:3, PC ae 
C42:2, SFA (PC), PC ae C34:2, PC ae C32:2, 
PC ae C40:4, PC ae C38:2, PC ae C42:4, SM 
C18:1, PC ae C38:0, SM C18:0, PC ae 
C34:3, PC ae C32:1, PC aa C40:3, PC ae 
C36:0, PC ae C38:6, PC aa C38:0, lysoPC a 
C17:0, SM (OH) C24:1, PC ae C36:3, PC aa 
C42:1, PC ae C42:5, PC aa C42:0, PC aa 
C42:4, PC aa C40:1, PC ae C44:6, PC aa 
C36:0, PC ae C38:4, SM C24:1, PC ae 
C36:5, PC ae C44:4, PC ae C38:5, SM 
C26:0, PC aa C32:0, PC aa C34:2, PC ae 
C30:0, SM C20:2, PC aa C38:1, lysoPC a 
C18:1, Total lysoPC, PC aa C40:2, PC aa 
C42:2, lysoPC a C18:0, PC aa C36:5, Total 
PC aa, Tyr, Total PC, PUFA (PC), Total 
(PC+SM), MUFA (PC), PC aa C38:5, PC aa 
C36:1, SM C24:0, PC ae C42:3, PC ae C40:1 
50 22 
2 
Aminoacids,  
phophatidyl-
cholines 
PC aa C40:5, AAA, PC aa C40:4, PC aa 
C38:3, Essential AA, PC aa C36:3, Total PC 
aa, Tyr, Total PC, PUFA (PC), PC aa C38:4, 
Total AA, Trp, PC aa C32:1, Total (PC+SM), 
BCAA, Val, His, PC aa C34:4, Ala, Total 
SM / Total PC, Total SM / Total (SM+PC), 
PC aa C36:4, Phe, Leu, Met, lysoPC a C14:0, 
Ile, MUFA (PC), Lys, lysoPC a C20:3, PC aa 
C38:5, PC aa C34:1, alpha-AAA, PC aa 
C36:1, SM C24:0, PC aa C30:0, PC aa 
C32:2, Pro, H1, PC aa C36:2, Glu, PC aa 
C34:3, lysoPC a C16:1 
23 10 
3 
Short-,  
medium- and 
 long-chain 
acylcarnitines 
C14:1, C12:1, C2, Total AC-DC / Total AC, 
C14, C16, C16:1, C12, C14:2, C7-DC, 
C18:1, Total AC-OH / Total AC, C14:1-OH, 
C16:1-OH, Total AC / C0, C10:1, C10, C2 / 
C0, (C2+C3) / C0, C8, C6 (C4:1-DC), C9, 
C14:2-OH, C10:2, C18, C5-DC (C6-OH) 
16 7 
4 
Phosphatidyl-
cholines, 
lysophosphatidyl-
cholines 
lysoPC a C26:1, lysoPC a C24:0, lysoPC a 
C28:1, PC aa C24:0, PC ae C30:1, Spermine, 
PC ae C44:3, PC ae C42:1, PC aa C26:0, 
lysoPC a C26:0, lysoPC a C28:0, SDMA, PC 
ae C30:2, PC ae C42:0,Met-SO / Met, PC ae 
C42:3, PC ae C40:1, Asp, Met-SO, Total 
DMA / Arg 
14 6 
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Associations between acylcarnitines and arterial stiffness in osteoarthritis 
patients 
Cr-PWV and cf-PWV were positively correlated with several acylcarnitines in 
the OA group (Table 13a). Furthermore, C14-OH, C16, C16:1-OH and C18 
were significantly associated with radiographic severity of OA after accounting 
for multiple testing. Component scores of component 3 were positively 
correlated with cf-PWV (r=0.25, p=0.037) and cr-PWV (r=0.35, p=0.003) in the 
OA group. In the control group neither the acylcarnitines nor the component 
scores derived from PCA were significantly associated with markers of arterial 
stiffness (Table 13b). 
 
Table 13a. Spearman correlation coefficients for the acylcarnitines associated with 
arterial stiffness in the osteoarthritis group. 
Variable cf-PWV 
(m/s) 
cr-PWV  
(m/s) 
PWV-ratio 
(m/s) 
OA-severity 
C12:1 0.247 0.309* –0.059 0.157 
C14 0.156 0.302* 0.001 0.272 
C14:1-OH 0.321* 0.216 –0.168 0.337* 
C14:2 0.316* 0.315* –0.112 0.240 
C16 0.176 0.304* –0.027 0.306* 
C16:1 0.238 0.263 –0.113 0.099 
C16:1-OH 0.117 0.367* 0.052 0.351* 
C18 0.036 0.290* 0.123 0.332* 
 
Table 13b. Spearman correlation coefficients for the acylcarnitines associated with 
arterial stiffness in the control group. 
Variable cf-PWV (m/s) 
m 
cr-PWV  
(m/s) 
PWV-ratio 
C12:1 0.096 0.074 –0.018 
C14 0.175 0.004 0.092 
C14:1-OH 0.223 –0.064 0.204 
C14:2 0.104 0.153 –0.017 
C16 0.316 0.123 0.185 
C16:1 0.229 0.052 0.146 
C16:1-OH 0.278 0.112 0.164 
C18 0.122 –0.076 0.142 
Statistically significant (p<0.05) correlation coefficients are shown in bold and marked with *.  
P-values are accounted for multiple testing using the Benjamini-Hochberg method. 
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Even though none of the long- and medium-chained acylcarnitines presented in 
Table 13 was associated with PWV-ratio in the univariate analysis, acyl-
carnitines were significantly associated with PWV-ratio in the stepwise multiple 
regression analysis. After adjusting for potential confounders (Table 14), com-
ponent 3 (acylcarnitines), TNF-α, age, gender and W/H-ratio remained inde-
pendently associated with PWV-ratio in the OA group (R2=0.46, p<0.001). 
 
Table 14. Table describing independent predictors of PWV-ratio in osteoarthritis 
patients. 
Variable Standardized 
coefficient 
Standard error p value 
Age 0.58 0.01 0.001 
TNF-a 0.28 0.01 0.007 
W/H-ratio 0.25 0.29 0.014 
Component 3 (acylcarnitines) –0.30 0.02 0.026 
Gender –0.22 0.02 0.026 
R2=0.46, p<0.001 
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6. DISCUSSION 
6.1 Arterial stiffness and central haemodynamics  
in osteoarthritis (Papers I, II) 
Evidence has emerged that patients with OA have increased cardiovascular 
morbidity and mortality (Nüesch et al. 2011; Rahman et al. 2013), however, 
very little is known about the exact mechanism underlying this association. 
Arterial stiffness has been shown to be an independent determinant of 
cardiovascular morbidity and mortality and has been proposed as a surrogate 
endpoint for CVD (Townsend et al. 2015). We demonstrated in Paper I, II and 
IV that OA patients have increased central arterial stiffness compared to non-
OA controls.  
In Paper I we found significantly higher cf-PWV in the OA patients com-
pared to the controls of approximately the same age and BMI. Also, the level of 
AIx@75 was increased in the OA group after adjusting for potential con-
founders. In Paper II we demonstrated independent association between the 
severity of OA and cf-PWV. Parameters of arterial stiffness have rarely been 
studied in OA patients. A study (Saleh et al. 2007) found association between 
hand OA and cf-PWV but it was largely attributable to the confounding effect 
of age. Another study (Goldsmith et al. 2014) found no difference in arterial 
stiffness between subjects with and without knee bone marrow lesions. The 
discrepancy between their results and ours might at least partly be explained by 
the fact that our study patients had more advanced OA. Because of pain and 
functional disability, the level of physical activity is limited in the advanced 
stages of OA. Since physical activity is associated with arterial stiffness (Ashor 
et al. 2014), increased pain and higher functional disability status might also 
partly explain the increased arterial stiffness in OA patients. In support of our 
hypothesis, a recent study has also found elevated stiffness of the aorta in end-
stage OA patients (Belen et al. 2016). Many factors, such as reduced physical 
activity, inflammation and OxS, which are characteristic of end-stage OA 
patients, might be responsible for the stiffer arteries. Accumulation of advanced 
glycation end-products is a feature of ageing that is present in both diseases 
(Goldin et al. 2006). Obesity is a known risk factor for both OA and CVD.  
Another plausible explanation for the association of CVD with OA is that 
vascular pathology might be involved in development of OA. Vascular damage 
to the subchondral bone has been proposed as a possible initiator of OA 
(Findlay, 2007). Blood supply to the subchondral bone region may be disturbed 
by microemboli and venous stasis. Highly vascularized epiphysis is mainly 
supplied with blood via the epiphyseal artery, which makes this region of high 
nutrient demand particularly susceptible to perfusion insufficiencies. In support 
of this hypothesis, a study (Chang et al. 2014) found that osteoblasts and 
chondrocytes from osteoarthritic joints suffer from hypoxia. Furthermore, they 
also found that hypoxia induced production of MMP 9 and proangiogenic 
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factors and caused reduction in osteoblast mineralized bone nodule formation, 
which are all characteristic of OA.  
In Paper I, cf-PWV was positively correlated with urea in OA patients. Since 
urea is the end-product of amino acid metabolism, this association highlights 
the possible role of altered amino acid metabolism in OA patients. Changes in 
amino acid profiles and impaired kidney function have been shown to 
contribute to increased arterial stiffness (Chue et al. 2010; Jung et al. 2014). On 
the basis of eGFR levels, which were approximately the same across both 
groups in this study, there was no difference in the kidney function. After 
adjusting for the effects of age and MAP, the association between urea and cf-
PWV was no longer significant. Higher applied forces (higher BP) in the aorta 
and ageing are strong independent predictors of cf-PWV (McEniery et al. 
2007). It is therefore important to adjust for mean pressure and age when 
evaluating predictors of cf-PWV. In the present study, the association between 
urea level and cf-PWV was largely due to the confounding effects of age and 
MAP. Additional analysis exploring the effects of body composition, smoking 
status, functional status and use of anti inflammatory drugs on arterial stiffness 
in OA patients should be within the scope of future studies. Altogether, our 
study suggests that increased central arterial stiffness is associated with OA and 
might at least partly be responsible for the higher CVD risk in this population. 
 
 
6.2 The impact of adipokines and  
matrix metalloproteinase 3 in osteoarthritis and  
in cardiovascular diseases (Paper II) 
Paper II demonstrates associations between adipokines, MMP3, arterial 
stiffness and OA severity in older adults with hip and knee OA in comparison 
with asymptomatic controls.   
The adipokines are a growing family of white-adipose-tissue derived factors 
that have multiple functions through different pathways and are involved in 
inflammation and modulation of immunological response but also in glucose 
and lipid metabolism (Gualillo et al. 2007). Many adipokines have been asso-
ciated with OA. Leptin has proinflammatory properties and complex actions on 
chondrocytes. Leptin upregulates MMPs and induces cartilage loss (Koskinen et 
al. 2014); however, its anabolic effects have also been described (Berry et al. 
2011). Although leptin has been associated with OA severity (Ku et al. 2009), 
the pathophysiological pathways are not fully understood. In addition to bone 
and cartilage, leptin also influences the cardiovascular system. It is an inde-
pendent predictor of myocardial infarction and stroke and has been associated 
with increased arterial stiffness (Gonzalez et al. 2013) through promoting 
inflammation and MMP upregulation (Scotece et al. 2012). In accord with 
previous studies, we found elevated expression of leptin in OA patients and, in 
addition, inverse association with OA radiographic grade, which might indicate 
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the anabolic effect of leptin. These findings point to the possible key role of 
leptin in the pathogenesis of OA and allow to suggest leptin as a link between 
OA and vascular damage. 
Adiponectin is prevalently synthesized in the adipose tissue and circulates in 
blood in large quantities (Kadowaki & Yamauchi, 2005). Adiponectin has anti-
inflammatory properties and hypoadiponectinemia has a detrimental effect on 
aortic stiffness (Tsioufis et al. 2007). In Paper II, adiponectin correlated inversely 
with large artery elasticity index and positively with AIx@75. Findings similar 
to ours have been reported for essential hypertension (Mahmud & Feely, 2005), 
but inverse association was recently found in juvenile idiopathic arthritis 
patients (Ilisson et al. 2015). Our results suggest that adiponectin as well as leptin 
might link OA with increased arterial stiffness. These findings describe the 
pleiotropic role of adipokines in OA and require further research to determine 
their potential as therapeutic targets.  
MMP3 is a catabolic enzyme that has not only the ability to degrade the 
extracellular matrix but plays a central role in activating other members of the 
MMP family (Chen et al. 2014). In Paper II we demonstrated higher level of 
MMP3 in OA patients compared to controls as well as positive correlation 
between radiographic severity of OA and serum level of MMP3 these patients. 
Activation and secretion of MMP3 are driven by inflammatory cytokines, which 
in turn enhances the production of inflammatory mediators like interleukin-1 
(Chen et al. 2014). This is in line with our results, according to which the OA 
group also showed higher values of WBC, which indicates a systemic inflam-
matory state. Furthermore, MMP3 is likely to influence arterial stiffness and has 
been found to be elevated in the atherosclerotic aorta (Knox et al. 1997; 
Agrotis, 2005). In conclusion, MMP3 might be a marker that links vascular 
pathology to OA. 
  
6.3 Metabolic syndrome and oxidative stress  
in osteoarthritis (Paper III) 
MetS is more prevalent among OA patients than in the general population 
(Singh et al. 2002). Several studies have found association between OA and 
components of MetS (Yoshimura et al. 2011, 2012; Shin, 2014). Dyslipidemia 
is an important feature of MetS and many epidemiological studies have reported 
altered serum lipid profiles among the OA population (Hart et al. 1995; Al-Arfaj, 
2003). However, the exact mechanisms involved are poorly yet understood. In 
Paper III we found independent association between LDL-cholesterol and OA 
severity. These findings suggest the potential role of LDL-cholesterol in OA 
progression. LDL-cholesterol has been extensively studied in CVD while 
studies focusing on LDL-cholesterol and OA are far more infrequent. Animal 
studies have indicated that cholesterol is involved in the pathogenesis of OA 
(Gierman et al. 2014). In healthy cells, LDL-receptors are down-regulated after 
activation, but in OA the regulatory mechanism is aberrant and leads to 
cholesterol accumulation (de Munter et al. 2013). LDL-cholesterol has also 
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been associated with synovial activation and osteophyte formation (de Munter 
et al. 2013). According to a recent study, LDL-receptor-related protein 1 is a 
modulator of MMP13 extracellular levels, which might also contribute to the 
association between OA severity and LDL-cholesterol (Yamamoto et al. 2016). 
Altogether, LDL-cholesterol seems to play an important role in the pathogenesis 
of OA. 
Furthermore, the particles of LDL are susceptible to ROS, which and results 
in increased formation of oxLDL particles that might be even more important in 
the pathogenesis of OA. The oxLDL is taken up via scavenger receptors, such 
as lectin type oxLDL receptor 1 (LOX-1), which leads to activation and 
secretion of different proteases and inflammatory mediators (de Munter et al. 
2016). The receptors of oxLDL are expressed on macrophages, endothelial cells, 
chondrocytes and fibroblasts. In Paper III we found that oxLDL was associated 
with OA severity as well as with MetS score. These results suggest that OA 
severity is associated with OxS independently of the effect of MetS. Moreover, 
the association between OxS and OA severity remained significant after 
correcting for BMI, age, gender and accounting for multiple testing, while the 
association between components of MetS and OA severity did not. The present 
study suggests that OxS is the result of both the increased amount of ROS and 
decreased antioxidative capacity. The sources of ROS contributing to oxidative 
damage include free radicals generated from aerobic metabolism and in 
response to specific stimuli like cytokines and growth factors. Several com-
ponents of MetS have been found to be associated with OxS (Roberts & Sindhu, 
2009). Since TAC is a relatively new marker and has rarely been studied in OA 
patients, the results are inconclusive (Altindag et al. 2007; Altay et al. 2015). 
Decreased antioxidative capacity might result from the high amount of ROS as 
well as from the dysfunction of the regulatory mechanisms of antioxidants 
(Lepetsos & Papavassiliou, 2016). In conclusion, we found that OxS was 
associated with OA, but further research is required for a better understanding 
of the role of OxS in OA and for possible clinical implications. 
Altered glucose metabolism is the core pathology of MetS and has been the 
focus of several epidemiological studies investigating metabolic OA (Hart et al. 
1995; Yoshimura et al. 2011, 2012). However, the results concerning insulin 
resistance and OA are inconsistent; nor have many studies adjusted for the 
effect of body composition and age, which are important confounders. The 
present thesis (Paper III) describes a trend towards positive correlation between 
radiographic severity of OA and insulin resistance.  
Hypertension has been associated with OA in many studies, but only a few 
of them have found significant association after adjusting for age and BMI 
(Yoshimura et al. 2012; Monira Hussain et al. 2014). In the current study we 
found a trend towards positive correlation between systolic BP and OA after 
correcting for the confounders and multiple testing. However, the arterial patho-
logy accompanying OA and MetS is probably more complex than hypertension. 
Assessment of arterial stiffness, besides hypertension, might provide a more 
profound insight into the arterial pathology involved in metabolic OA. 
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6.4 The role of acylcarnitines as biomarkers  
in osteoarthritis (Paper IV) 
In Paper IV we found independent association between arterial stiffness and 
serum acylcarnitines in end-stage OA patients. Several serum medium- and 
long-chain acylcarnitines were associated with radiographic severity of OA. 
Furthermore, the levels of acylcarnitines were significantly lower in the OA 
patients than in the age- and gender-matched controls. 
Acylcarnitines are essential for transport of fatty acids into mitochondria 
during the process of β-oxidation, which is a major source of energy. We found 
that several medium- and long-chain acylcarnitines such as C14, C14:2, C14:1-
OH, C16, C16:1-OH and C18 were significantly lower in the OA group. Similar 
findings have been found in early rheumatoid arthritis patients (Surowiec et al. 
2016). The lower level of acylcarnitines might be caused by increased energy 
consumption in OA. One of the causes of increased energy expenditure is 
inflammation. Low-grade systemic inflammation has an important role in the 
pathogenesis of OA (Berenbaum, 2013) and has also been associated with 
arterial stiffening and endothelial dysfunction (Steyers & Miller, 2014). In 
support, we found that TNF-α was independently associated with arterial 
stiffness in the linear regression model and the serum levels of TNF-α, hs-CRP 
and WBC were higher in the OA patients compared with the controls. It has 
been noted that in end-stage OA, chondrocytes become hypertrophic as meta-
bolic activity increases (van der Kraan & van den Berg, 2012). These changes 
might also be associated with inflammation involving increased production of 
inflammatory mediators and proteolytic enzymes (e.g. MMPs). 
Recently, a study (Zhang et al. 2014) described two different subtypes of 
knee OA based on different synovial fluid acylcarnitine concentrations and 
activity of acetyltransferase. In support, our study found that acylcarnitines were 
positively correlated with OA radiographic severity. These changes are in 
accordance with a study reporting accumulation of lipid particles in the 
chondrocytes in the later stages of OA (Villalvilla et al. 2013). In addition to 
lower acylcarnitine levels, we also found decreased levels of the CPT-ratio and 
total AC/C0 ratio in the OA patients. These ratios describe the activity of 
enzymes responsible for acylcarnitine metabolism. Moreover, CPT is respon-
sible for condensation of activated long-chain fatty acids into carnitine to form 
acylcarnitines, thereby regulating the entry of acyl-coenzyme-A into the mito-
chondrial matrix (Turner et al. 2007). The level of the CPT-1-ratio describes the 
activity of CPT-1, which is a rate-limiting enzyme for β-oxidation of long-chain 
fatty acids. Thus, the decreased levels of serum acylcarnitines in the OA 
patients might be related to dysfunctional enzymes of fatty acid β-oxidation.  
We found that acylcarnitines were positively correlated with arterial stiff-
ness. In regression analysis, component 3 (acylcarnitines) was an independent 
predictor of the PWV-ratio. Cr-PWV describes stiffness of the peripheral 
muscular arteries; as it had stronger association with acylcarnitines than cf-
PWV, it might have greater influence on the association between the PWV-ratio 
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and acylcarnitines in OA patients. The PWV-ratio describes the arterial stiffness 
mismatch phenomenon. The peripheral arteries are physiologically stiffer than 
the aorta. The physiological gradient of stiffness creates backward travelling 
pulse waves from the reflection sites. Thereafter, the forward travelling pressure 
wave is dampened and peripheral microcirculation is protected from high 
pulsatile pressure. Ageing and different diseases increase aortic stiffness to a 
point where it is higher than peripheral muscular artery stiffness. This pheno-
menon is described as stiffness mismatch and it results in higher pressure and 
energy transmission to the microcirculation (McEniery et al. 2005; Mitchell et 
al. 2010). Our study showed for the first time that OA patients’ serum acyl-
carnitine levels were associated with arterial stiffness and stiffness mismatch, 
while there was no such association in the control group. Acylcarnitines have 
been found to be predictive of future CVD events (Shah et al. 2012). Alto-
gether, medium- and long-chain acylcarnitines entail great potential for CVD 
risk assessment and might also explain the association between OA and CVD. 
 
 
6.5 Limitations 
The present thesis (Papers I–IV) has several limitations that must be acknow-
ledged when interpreting the results. Firstly, the cross-sectional study design is 
not appropriate for proving causal relationships. Thus, the results of the study 
should be confirmed or overruled in future prospective studies. Secondly, as the 
control group was not radiographically tested for absence of OA, it might have 
included asymptomatic OA patients, which might introduce a type II error. 
Another limitation of the study is the potential confounding role of different 
uses of nonsteroidal anti-inflammatory drugs across the study groups. End-stage 
OA patients use several medications to alleviate pain, which include NSAIDs. 
Since many NSAIDs increase the CVD risk, this might also have influenced the 
results of the study. 
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7. CONCLUSIONS 
1. Carotid-femoral pulse wave velocity (cf-PWV) were significantly increased 
and small artery elasticity index was significantly decreased in the end-stage 
osteoarthritis patients compared with age- and gender matched controls. The 
level of cf-PWV was independently associated with radiographic severity of 
osteoarthritis. Thus, arterial stiffening is linked to osteoarthritis and might 
play a role in the increased cardiovascular risk in these patients.  
2. The serum levels of leptin and matrix metalloproteinase 3 (MMP3) were 
significantly higher and the serum levels of adiponectin were significantly 
lower in the end-stage osteoarthritis patients compared with the controls. The 
serum level of adiponectin was significantly correlated with augmentation 
index and large artery elasticity and the level of MMP3 correlated with 
severity of osteoarthritis in the osteoarthritis patients. Thus, measurement of 
adipokines and MMP3 provides relevant clinical information about the 
vascular function and severity of osteoarthritis. 
3. The serum levels of LDL-cholesterol and oxidized LDL-cholesterol were 
increased and independently correlated with osteoarthritis severity in the 
end-stage osteoarthritis patients. Elevated serum C-peptide, total peroxide 
concentrations and lower total antioxidant capacity were found in the 
osteoarthritis patients. High grade oxidative stress and dyslipidemia might 
influence the clinical course of osteoarthritis and could therefore serve as 
important therapeutic targets and diagnostic biomarkers. 
4. The levels of long- and medium-chain acylcarnitines were significantly 
lower in the end-stage osteoarthritis group. These acylcarnitines were 
independently associated with the pulse wave velocity ratio and osteo-
arthritis severity in the osteoarthritis patients. Therefore, shifts in lipid meta-
bolism provide valuable information for a better understanding of how 
metabolic pathways are involved in the pathogenesis of osteoarthritis and 
arterial stiffening. 
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SUMMARY IN ESTONIAN  
Osteoartroosi kardiovaskulaarne ja  
metaboloomiline profileerimine 
Osteoartroos (OA) on krooniline progresseeruv liigeshaigus, mis haarab sage-
damini põlve, puusa ja käe liigeseid ning lülisammast. Muskuloskeletaalhai-
gused on üks suuremaid haigena elatud aastate põhjustajaid. Juba ainuüksi 
põlve OA mõjutab 250 miljonit inimest. Lisaks on leitud, et praktiliselt igal 
teisel inimesel tekib elu jooksul sümptomaatiline põlve OA. Sellest tulenevalt 
on haiguse sotsio-ökonoomiline mõju suur. Vaatamata suurele huvile pole täna-
seni võimalik OA patsienti terveks ravida. Parim ravi keskendub valu vähenda-
misele ja funktsiooni säilitamisele ning lõppstaadiumis endoproteesimisele, mis 
on küll väga efektiivne patsientide elukvaliteedi parandamisel, aga toob endaga 
kaasa mitmed riskid. Seetõttu on hädavajalik haiguse protsesside täiendav 
uurimine, et leida paremaid ravimeetodeid. 
OA on heterogeenne haiguse grupp, mis omab mitmeid seoseid teiste haigus-
tega. Üheks oluliseks OA riskifaktoriks on rasvumine. Tegemist on arenenud 
maailmas üha sageneva probleemiga. Ühest küljest avaldab ülekaal otseselt 
mehhaanilist survet raskust kandvatele liigestele, mis tõstab liigese traumaatilise 
kahjustuse riski ja aktiveerib ka põletiku kaskaadi. Teisest küljest on leitud, et 
rasvumine on seotud ka raskust mitte kandvate liigeste OA-ga. Selles seoses 
võivad olulist rolli mängida adipokiinid, mis on peamiselt valge rasvkoe poolt 
sünteesitud bioaktiivsed ained. Adipokiinid, mille tuntumad esindajad on lep-
tiin, adiponektiin ja resistiin, omavad organismi homöostaasi säilitamisel olulist 
rolli ning rasvumise korral on nende normaalne tasakaal häirunud. OA korral on 
mitmete adipokiinide tase muutunud. Adipokiine on seostatud OA raskusastme 
ja haiguse progresseerumisega. Seetõttu omavad nad suurt potentsiaali aitamaks 
diagnoosida OA varasemas staadiumis ning ennustada haiguse edasist kulgu. 
Lisaks muutustele adipokiinide tasemes tõstab rasvumine oksüdatiivse stressi 
taset, mis väljub organismi antioksüdatiivse süsteemi kontrolli alt ja põhjustab 
kudede kahjustusi.  
Varasemad uuringud on näidanud, et OA patsientidel esineb rohkem südame- 
ja veresoonkonna haigusi. Selle taga võivad olla ühised riskifaktorid nagu vanus, 
ülekaalulisus, ravimite kõrvaltoimed ja vähene füüsiline aktiivsus. Teisest küljest 
on OA ja ateroskleroosi patogeneesis mitmeid ühiseid radu. Seetõttu võivad OA 
ja veresoonte haigused olla omavahel seotud. Tegemist on uudse lähenemisega 
ja vähe uuritud valdkonnaga. Üheks südame- ja veresoonkonna haiguste riski-
markeriks on arterite jäikus. Arterite jäikuse mõõtmine mitteinvasiivselt on 
lihtne ja usaldusväärne metoodika, mis võimaldab hinnata organismi veresoonte 
seisundit. Arterite jäikuse mõõtmise kuldseks standardiks loetakse aordi pulsi-
laine levikukiiruse (cf-PWV) kindlaks tegemist. cf-PWV on sõltumatu südame 
ja veresoonkonna haiguste ja suremuse ennustaja.  
Nii veresoonte jäigenemise kui ka OA korral toimuvad organismi ainevahe-
tuses mitmed muutused, mille selgitamine võimaldaks täiustada teadmisi OA 
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olemusest ning pakkuda välja uusi ründepunkte haiguse ravimiseks. Metabo-
loomika on uus ja kiiresti arenev teadusvaldkond, mis hindab organismi madal-
molekulaarsete metaboliitide profiili. See on nn “oomika” teaduste viimane lüli, 
mis annab ülevaate organismi hetkeolukorrast, kui mõju on avaldanud nii 
geneetilised tegurid, epigeneetilised tegurid kui ka keskkond. Metaboloomika 
annab võimaluse uurida OA ja südame- ning veresoonkonna haiguste oma-
vahelisi seoseid uuel tasandil.  
 
 
Uurimuse eesmärgid 
Antud doktoritöö üldiseks eesmärgiks oli uurida osteoartroosiga patsientide 
arterite jäikust, metaboolseid kõrvalekaldeid, oksüdatiivset stressi ning madal-
molekulaarsete metaboliitide profiili ning võrrelda neid vanuse ning soo poolest 
sobitatud kontrollgrupiga. See on vajalik, et selgitada kardiovaskulaarse riski 
seost osteoartroosiga ning otsida uusi biomarkereid osteoartroosi varaseks 
diagnoosimiseks ja haiguskulu ennustamiseks. 
Uuringu täpsemad eesmärgid: 
1. Mõõta arterite jäikust osteoartroosiga patsientidel võrreldes kontrollgrupiga 
ning uurida arterite jäikuse seoseid osteoartroosi raskusega. 
2. Määrata adipokiinide (leptiin, adiponektiin) ja maatriksi metalloproteinaas 
3 taset osteoartroosiga patsientidel ja kontrollgrupil ning uurida nende bio-
molekulide seoseid arterite jäikuse ja osteoartroosi raskusega.  
3. Hinnata metaboolse sündroomi ja oksüdatiivse stressi mõju osteoartroosiga 
patsientidele ja kontrollgrupile. 
4. Määrata atsüülkarnitiinide mõju arterite jäikusele ning osteoartroosi ras-
kusega osteoartroosiga patsientidel ning kontrollgrupil.  
 
 
Uuringu meetodid 
Uuringusse kaasati 70 lõpp-staadiumis põlve ja puusa primaarse OA patsienti 
(Tartu Ülikooli Kliinikumi ortopeedia osakonnast) ja 82 vanuse ning soo 
poolest sobitatud kontrollgrupi liiget (perearstide nimistutest). Arterite jäikust 
hinnati pulsilaine leviku kiiruse ja pulsilaine analüüsi metoodikaga mitteinva-
siivselt Endoteeli Keskuses. OA raskusastet hinnati radioloogiliselt Kellgren-
Lawrence klassifikatsiooni järgi. Biomarkerite ja madalmolekulaarsete meta-
boliitide mõõtmine tehti Tartu Ülikooli bio- ja siirdemeditsiini instituudi bio-
keemia osakonnas ning Tartu Ülikooli Kliinikumi Ühendlaboris. 
 
 
Tulemused ja järeldused 
1. Osteoartroosiga patsientide arterite jäikus oli märgatavalt kõrgem kui vanuse 
ja soo poolest sobitatud kontrollgrupil. Lisaks esines sõltumatu seos 
80 
osteoartroosi raskusastme ja arterite jäikuse vahel, mis viitab veresoonte 
kahjustuse rollile osteoartroosi arengus. 
2. Osteoartroosiga patsientide leptiini tase oli kõrgem ja adiponektiini tase 
madalam kui kontrollgrupil. Selgus, et osteoartroosi raskusaste on seotud 
maatriksi metalloproteinaas 3 ja leptiini tasemega ning adiponektiin on seo-
tud arterite jäikusega osteoartroosiga patsientidel. Seega võivad need valgud 
tulevikus osutuda osteoartroosi biomarkeriteks. 
3. Osteoartroosiga patsientide oksüdatiivse stressi tase oli oluliselt kõrgem kui 
kontrollgrupil. Metaboolse sündroomi ükski komponent ei olnud sõltumatult 
seotud osteoartroosi raskusastmega, aga C-peptiidi tase oli oluliselt kõrgem 
osteoartroosiga patsientidel ning LDL-kolesterooli tase oli seotud osteo-
artroosi raskusastmega. Seega näitasid uuringu tulemused liigset oksüda-
tiivset stressi ja lipiidide ning glükoosi ainevahetuse häireid osteoartroosiga 
patsientidel. 
4. Osteoartroosiga patsientide keskmise ja pika ahelaga atsüülkarnitiinide 
tasemed oli madalamad võrreldes kontrollgrupiga. Lisaks esines sõltumatu 
seos atsüülkarnitiinide ja arterite jäikuse vahel. Seega võivad atsüülkarni-
tiinid osutuda tulevikus olulisteks osteoartroosi biomarkeriteks, olles abiks 
haiguse diagnoosimisel ja edasise kulu ennustamises. 
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